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Preâmbulo
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desenvolvia na área da imagiologia cardíaca. 
Testemunhei o início da aplicação da tomografia computorizada para 
estudo das artérias coronárias no Serviço e tenho acompanhado o 
alargamento da ressonância magnética e tomografia computorizada 
cardíacas a novas situações clínicas.
Um destes campos activos de pesquisa é a diabetes mellitus. Pela 
natureza tipicamente assintomática da diabetes mellitus tipo 2, as suas 
manifestações e complicações, nomeadamente no foro cardiovascular, 
são reconhecidas tardiamente. Neste âmbito, o estudo de novas técnicas 
de imagem não-invasiva, poderá permitir conhecer melhor o espectro de 
alterações cardíacas condicionadas pela diabetes mellitus tipo 2.
Acabou por ser com enorme motivação que recebi o desafio para tentar 
aprofundar o conhecimento na área da imagiologia cardíaca e a sua 
aplicação no estudo de novos marcadores de doença cardiovascular em 
pacientes com diabetes mellitus tipo 2.
O trabalho que culmina na presente Tese só foi possível com o recurso a 
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do projecto, bem como a perspicácia e o espírito crítico e construtivo que 
foram decisivos na orientação e edificação deste trabalho.
A presente Dissertação também não teria sido possível sem o entusiasmo 
pela investigação científica, brilhantismo e dinamismo manifestados pelo 
Senhor Professor Doutor Miguel Castelo Branco, que, ao conceber o estudo 
“Diamarker”, proporcionou os meios imprescindíveis para a persecução 
desta investigação. Agradeço aos Senhores Professores Doutores Filipe 
Caseiro Alves e Miguel Castelo Branco a generosidade e confiança que 
depositaram em mim ao acolher-me como investigador no projecto 
“Diamarker”.
À Senhora Professora Doutora Maria João Ferreira, que generosamente 
aceitou co-orientar a presente Dissertação, agradeço a sua permanente 
disponibilidade, brilhante inteligência e profundo saber científico, que 
moldaram de forma decisiva este trabalho.
Ao Senhor Professor Doutor Paulo Donato faço um agradecimento 
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Mas faço um agradecimento particular aos meus colegas Médicos, que 
aceitaram quase sempre atrasar o seu trabalho assistencial, e que, algumas 
vezes na minha ausência, substituíram-me na execução dos exames de 
imagem.
Neste âmbito, pela logística que acarreta, o trabalho mais afectado foi o 
da tomografia computorizada. O meu agradecimento á Drª Luísa Teixeira 
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Introduction
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, 
or both. The chronic hyperglycemia of diabetes is associated with long-
term damage, dysfunction, and failure of different organs, especially the 
eyes, kidneys, nerves, heart, and blood vessels. The causes of diabetes are 
multiple. Both genetic and environmental factors play roles in its etiology. 
The supply of insulin may be reduced by a decrease in pancreatic β cell mass 
and/or functional disturbances of β cells. In other cases there are both insulin 
resistance and relative deficiency of insulin. 
If the metabolic abnormality is mild, patients may be asymptomatic, while in 
the presence of overt hyperglycemia, characteristic symptoms such as thirst, 
polydipsia, polyuria and weight loss often arise. In severe cases, ketoacidosis 
or hyperglycemic–hyperosmolar states may occur and lead to disturbances 
of consciousness, coma and even death unless treated appropriately.
The duration of this metabolic disorder leads to diabetes-specific 
complications, chiefly involving small vessels (retinopathy, nephropathy and 
neuropathy), resulting in serious outcomes such as visual disturbance, renal 
failure, and gangrene. Diabetes accelerates and exacerbates the occurrence 
of arteriosclerosis, increasing the risks for coronary disease, cerebrovascular 
disease and peripheral artery disease (1-3).
An increasingly obese and aged population heralds a global epidemic of 
diabetes mellitus, which poses a major risk to individual and public health.
1. Classification
The classification of diabetes mellitus comprises four categories: type 1, type 
2, other types, and gestational diabetes.
Type 1 diabetes mellitus covers those cases where disease is due to pancreatic 
islet beta-cell destruction. This can be idiopathic or more commonly is due to 
autoimmune processes. It does not include cases where beta-cell destruction 
is due to a specific disease such as cystic fibrosis. Type 2 diabetes covers those 
cases that result from defects in insulin secretion and is often combined 
with a degree of insulin resistance. This category covers a large range of 
mechanisms from defective insulin secretion with no insulin resistance to 
largely insulin resistance with a degree of defective secretion. The deficiency 
in insulin secretion is usually relative rather than absolute (1-3).
Other specific types of diabetes include other etiopathogenic mechanisms, 
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e.g., genetic defects in b-cell function, genetic defects in insulin action, 
diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or 
chemical-induced (such as in the treatment of HIV/AIDS or after organ 
transplantation). Gestational diabetes mellitus refers to a state of glucose 
intolerance occurring or detected for the first time during pregnancy (1-3).
2. Diagnosis
The diagnosis of diabetes mellitus is established when a patient presents 
with classic symptoms of hyperglycemia (thirst, polyuria, weight loss, 
blurry vision) and has a random blood glucose value of 200 mg/dL 
(11.1 mmol/L) or higher, and confirmed on another occasion. In an 
asymptomatic individual the diagnosis can be established with any of the 
following criteria: fasting plasma glucose values ≥126 mg/dL (7.0 mmol/L), 
two-hour post oral glucose test values of ≥200 mg/dL (11.1 mmol/L), and 
hemoglobin A1c values ≥6.5%. An abnormal result should be confirmed 
by repeat measurement with the same test (1-3).
Prediabetes
It is recognized an intermediate group of individuals whose glucose 
levels, although not meeting criteria for diabetes, are nevertheless too 
high to be considered normal and have a relatively high risk for the future 
development of diabetes. The onset of type 2 diabetes is gradual, with 
most individuals progressing through a state of prediabetes, which is 
defined as one or more of the following: fasting plasma glucose 100 to 125 
mg/dL (5.6 to 6.9 mmol/L), two-hour post oral glucose test values of 140 
to 199 mg/dL (7.8 to 11.0 mmol/L) or hemoglobin A1c 5.7% to 6.4% (1-3). 
Although individuals can spend years in a prediabetes stage, an expert 
American Diabetes Association (ADA) panel estimated that up to 70% of 
individuals with prediabetes will eventually progress to type 2 diabetes 
(2).
3. Epidemiology
The number of people with diabetes is increasing due to population 
growth, aging, urbanization, and increasing prevalence of obesity and 
physical inactivity.
Diabetes mellitus is a major public health problem in the western world. 
The International Diabetes Federation estimates that in 2025 there will 
be 380 million diabetics, which corresponds to 7.1% of the population 
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between 20 and 79 years. In Europe it is considered that affects about 60 
million people: 10.3% of men and 9.6% of women over 25 (3). The number 
of diabetics has been growing also in Portugal. The last Report of the 
National Observatory of Diabetes, pointed to a prevalence of 12.3% in the 
population between 20 and 79 years and an incidence of 511.4 new cases 
per 100 000 inhabitants (4).
Type 2 diabetes mellitus is the commonest type of diabetes accounting 
for between 80 and 95% of cases of diabetes. 
4. Diabetes and the heart
Type 2 diabetes, the most common form of the disease, may remain 
undetected for many years and physicians often face this disease at an 
advanced stage, when vascular complications have already occurred in 
most of patients.
Cardiovascular disease is the leading complication of type 2 diabetes 
and approximately one half of patients with type 2 diabetes will die of 
a cardiovascular cause (5). Indeed, the National Cholesterol Education 
Program report from the United States and guidelines from the European 
Society of Cardiology consider type 2 diabetes to be a cardiovascular 
equivalent (6, 7), thereby establishing diabetics a high risk population. This 
classification was based in part upon the observation that patients with 
type 2 diabetes without a prior myocardial infarction were at the same 
risk for myocardial infarction and coronary mortality as patients without 
diabetes who had a prior myocardial infarction (8).
Apart from an increased incidence, coronary artery disease is also 
more extensive and accelerated among diabetic patients (9). Diabetic 
individuals have a higher incidence of two-and three-vessel disease and 
a greater number of diseased vessel segments than do their nondiabetic 
counterparts (10). Multivessel coronary heart disease is also common in 
asymptomatic patients with type 2 diabetes (11). 
When coronary artery disease occurs in diabetics, the course of disease is 
particularly aggressive and associated with worse outcomes than in non-
diabetics (12). Diabetes is associated with an increased risk of myocardial 
infarction. In diabetics; following a myocardial infarction, the risk of a 
subsequent myocardial infarction and development of heart failure are 
higher than in non-diabetics (13). 
Furthermore, the presence of coronary atherosclerosis without significant 
luminal narrowing may not be entirely benign (14, 15). Indeed, previous 
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studies have demonstrated that myocardial infarction and unstable angina 
are frequently caused by coronary lesions deemed to be nonsignificant 
before the event (15). Plaque composition may be crucial to define coronary 
risk. In a histologic study of atherectomy specimens from patients with 
and without diabetes, coronary tissue from diabetics contained a greater 
amount of lipid-rich atheroma, more macrophage infiltration, both of 
which are associated with a greater risk for plaque rupture, and a higher 
incidence of thrombosis (16).
In addition to the increase in cardiovascular events, patients with type 
2 diabetes also have a high rate of asymptomatic coronary disease as 
determined by the presence of coronary artery calcification and by 
inducible silent ischemia on stress imaging (1, 6, 17). 
It has been well recognized that patients with type 2 DM have impaired 
coronary flow reserve reflecting coronary microvascular function even 
in the absence of epicardial coronary atherosclerosis (18, 19). Coronary 
microvascular dysfunction may be the underlying mechanism in patients 
with symptoms and signs of myocardial ischemia without angiographically 
detectable coronary artery disease, and has independent prognostic 
information in diabetic patients (19).
4.1 Diabetic cardiomyopathy
Chronic heart failure is a complex clinical syndrome that can result from 
any structural or functional cardiac disorder that impairs the ability 
of the ventricle to fill with or to eject blood. Systolic heart failure arises 
from a compromise in the contractility of the heart and is defined as a 
left ventricular ejection fraction of < 45%. Diastolic dysfunction interferes 
with the heart’s ability to relax and fill with blood.
The Framingham study firmly established the epidemiologic link between 
diabetes and heart failure (20). Coronary heart disease and arterial 
hypertension are the main mechanisms responsible for heart failure. 
However, heart failure in diabetes also occurs in the absence of underlying 
coronary artery disease and hypertension, an entity known as diabetic 
cardiomyopathy, that is defined based on exclusion of other potential 
causes. 
Diabetic cardiomyopathy development affects myocardial remodeling 
and eventually leads to cardiac diastolic and systolic dysfunction. 
Diastolic dysfunction is a major characteristic in diabetic cardiomyopathy. 
It has been reported that there is a significant impairment in diastolic 
function in individual with diabetes even without coronary artery disease 
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and overt heart failure (21-23). Studies on type 2 diabetic patients with 
normal blood pressure and glucose levels found a prevalence over 40% 
of diastolic dysfunction, compared to healthy controls (22, 23). Recently, 
studies with tissue Doppler strain analysis, could also detect systolic 
abnormalities in diabetic patients with normal left ventricular ejection 
fraction (24-26).
4.2 Diabetic cardiac autonomic neuropathy
Diabetic cardiac autonomic neuropathy encompasses damage to the 
autonomic nerve fibers that innervate the heart and blood vessels, 
resulting in abnormalities in heart rate control and vascular dynamics. 
Cardiac autonomic neuropathy is particularly associated with an 
increased risk of silent myocardial infarction and sudden cardiac death. 
Autonomic nervous system dysfunction is believed to be the primary 
underlying mechanism for impaired recognition of ischemia in diabetic 
patients. Supporting this hypothesis is the observation that the uptake of 
metaiodobenzylguanidine (MIBG), a norepinephrine analog, is reduced in 
diabetic patients with silent ischemia (27-29).  
The prevalence of cardiac autonomic neuropathy in type 2 diabetic 
patients is estimated to be around 20-30% of patients. 
Diabetic cardiac autonomic neuropathy has a wide range of manifestations: 
resting tachycardia, orthostatic hypotension, exercise intolerance, 
intraoperative cardiovascular liability, and silent myocardial infarction. The 
diagnosis of this entity is based on the evaluation of heart rate response 
to deep breathing, standing and Valsalva maneuver, and blood pressure 
response to standing. However, these tests are indirect assessments of the 
autonomic nervous system and are less sensitive than direct assessments 
by cardiac radionuclide imaging with SPECT or PET (27-29). 
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5. Mechanisms of cardiovascular disease in 
diabetes mellitus
The etiology of cardiovascular disease in diabetes is complex and 
multifactorial, mainly due to prolonged exposure to hyperglycemia 
clustering with other risk factors such as arterial hypertension, dyslipidemia, 
obesity, as well as genetic susceptibility. 
The development of cardiovascular disease in people with insulin 
resistance is a progressive process, characterized by early endothelial 
dysfunction and vascular inflammation leading to monocyte recruitment, 
foam cell formation and subsequent development of fatty streaks. Over 
many years, this leads to atherosclerotic plaques, which, in the presence 
of enhanced inflammatory content, become unstable and rupture to 
promote occlusive thrombus formation. 
5.1 Endothelial dysfunction, oxidative stress and 
vascular inflammation
Vascular endothelial cells play a major role in maintaining cardiovascular 
homeostasis. In addition to provide a physical barrier between the vessel 
wall and lumen, the endothelium secretes a number of mediators that 
regulate platelet aggregation, coagulation, fibrinolysis and vascular tone. 
Hyperglycemia, elevated free fatty acids, and insulin resistance which 
occur in states of diabetes mellitus, act in concert to target endothelial 
cells, resulting in oxidative stress and endothelial dysfunction (30-32).
Endothelial cells secrete several mediators that can alternatively mediate 
either vasoconstriction, such as endothelin and thromboxane A2, or 
vasodilation such as nitric oxide and prostacyclin.
Nitric oxide plays an important role in the regulation of vascular tone, 
inhibition of platelet aggregation, and suppression of vascular smooth 
muscle cell proliferation (31).
When the endothelium is dysfunctional, the vasoconstrictor effects are 
unopposed and arterial tone is increased. In addition, pathological states 
are associated with increased endothelial production of endothelin-1 and 
other endothelium-derived vasoconstrictors that may further promote 
vasospasm and increase arterial stiffness.
Reduction or loss of endothelial nitric oxide availability results in 
monocyte and vascular smooth muscle cell migration into the vascular 
intima layer and the formation of macrophage foam cells, the initial stages 
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of atherosclerosis (30-32).
Increased nutritional fatty acid intake and increased lipolysis in diabetes 
will lead to increased free fatty acid delivery to nonadipose tissues, such 
as muscle, liver, pancreas and also the heart (32, 33). 
The metabolic effects of type 2 diabetes mellitus on the myocardium have 
been previously described in experimental models, and include increased 
myocardial nonesterified fatty acid utilization, an increased glucose flux 
and subsequently triglyceride accumulation, and subsequent increased 
formation of reactive oxygen species. These processes, commonly referred 
to as “gluco-lipotoxicity,” contribute to decreased adenosine triphosphate 
synthesis, mitochondrial dysfunction, and finally to apoptosis of myocardial 
cells
5.2 Macrophage dysfunction
Extracellular deposition of lipids is followed by an inflammatory infiltrate 
of monocytes and T lymphocytes to form fatty streaks. Monocytes develop 
in to macrophages and scavenge modified lipids to form foam cells. The 
inflammatory infiltrate and foam cells secrete inflammatory mediators 
and produce reactive oxidative species resulting in the migration and 
proliferation of vascular smooth muscle cells (32-35).
5.3 Atherogenic dyslipidemia
Atherogenic dyslipidemia comprises a triad of increased blood 
concentrations of small, dense low-density lipoprotein particles, decreased 
high-density lipoprotein particles, and increased triglycerides. A typical 
feature of obesity, the metabolic syndrome, insulin resistance, and type 2 
diabetes mellitus, atherogenic dyslipidemia has emerged as an important 
risk factor for myocardial infarction and cardiovascular disease.
In type 2 diabetes, increased free fatty acid release to the liver, due to 
lipolysis, lead to enhanced hepatic dense low-density lipoprotein particles 
production.
The lipid profile of these subjects is characterized by high triglycerides, 
low high-density lipoprotein cholesterol, increased remnant lipoproteins, 
apolipoprotein B synthesis and small, dense low-density lipoprotein 
particles. This low-density lipoprotein particles subtype plays an important 
role in atherogenesis being more prone to oxidation (32-35).
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5.4 Coagulation and platelet function
Among factors contributing to the prothrombotic condition, which 
characterize patients with diabetes mellitus, platelet hyperreactivity plays 
a pivotal role. Platelets of diabetes mellitus patients are characterised 
by dysregulation of several signalling pathways leading to intensified 
adhesion, activation and aggregation.
Hyperglycaemia may increase platelet reactivity by glycating platelet 
surface proteins (impairing membrane fluidity and therefore increasing 
platelet adhesion), activating protein kinase C (a mediator of platelet 
activation) and inducing P-selectin (a surface adhesion protein) expression.
Insulin deficiency also plays an important role in platelet dysfunction 
by different mechanisms: increased intracellular calcium concentration 
leading to enhanced platelet degranulation and aggregation; impaired 
response to nitrous oxide and prostacycline, which enhances platelet 
reactivity (32, 34-36).
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Introduction
The present chapter reviews diabetic cardiovascular disease and illustrates 
the role of multimodality cardiac imaging in its assessment.
We will discuss: 
a) Diabetic heart disease, including: i. Myocardial dysfunction; ii. Metabolic 
heart disease; iii. Coronary artery disease; and iv. Cardiac autonomic 
neuropathy; 
b) Cerebrovascular disease, and 
c) Peripheral arterial disease. 
1. Myocardial dysfunction
1.1 Diastolic dysfunction
Diabetes mellitus affects both systolic and diastolic left ventricular (LV) 
function. Initially, myocardial dysfunction is only very subtle, without 
clinical symptoms, and often occurs before diabetes mellitus is apparent 
(1). The first signs of myocardial dysfunction manifest in diastole (2). In 
patients with type 2 diabetes mellitus, a high prevalence of diastolic 
dysfunction of 43%–75% (3, 4) and the occurrence of heart failure in the 
presence of preserved systolic function have been reported (5, 6).
Diastole is the period of the cardiac cycle between closure of the aortic 
valve and that of the mitral valve. During this time, the left ventricle relaxes 
and refills, ready for the next systolic contraction. Conventionally, diastole 
is divided into four physiological phases: (i) isovolumetric relaxation: 
from closure of the aortic valve to opening of the mitral valve; (ii) early 
rapid filling: due transmitral pressure gradient that drives LV filling;  (iii) 
diastasis: period of low flow in mid-diastole; (iv) late rapid filling: due to 
atrial contraction. 
Diastolic dysfunction is characterized pathophysiologically by impaired 
relaxation or abnormal myocardial passive properties. Consequently, 
with exercise, there is an inability to augment LV end-diastolic volume 
despite increasing LV end-diastolic pressure. With the development 
of early diastolic dysfunction, the proportion of LV filling permitted 
to occur in early diastole is reduced. The relative importance of atrial 
contraction is thus increased, so-called grade I diastolic dysfunction. As 
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diastolic dysfunction worsens, pressure raises within the left atrium, such 
that immediately following mitral valve opening, blood is forced under 
positive pressure, rather than sucked by negative pressure, into the left 
ventricle. Although the proportion of LV filling occurring in early diastole 
returns to normal, the underlying physiology is not normal, hence the 
designation of pseudonormal LV filling, or grade II diastolic dysfunction. 
Grade III diastolic dysfunction is characterized by a further increase in 
filling pressure that will increase the gradient between the left atrium and 
the left ventricle during early diastole. When filling pressures are high, flow 
into the ventricle will start early and filling will terminate quickly, but with 
reversibility with the Valsalva maneuver. Grade IV diastolic dysfunction is 
characterized by irreversibility with the Valsalva maneuver.
Currently, echocardiography is the method of choice for diastolic 
function testing in clinical practice. One of the first simple tests that is 
performed when evaluating diastolic function is the assessment of mitral 
inflow velocities from the leaft atrium to the left ventricle with pulsed-
wave Doppler ultrasonography (US) (Figure 1). Time-velocity curves are 
obtained from a sample volume positioned on the mitral leaflet tips, 
and waveform analysis results in quantification of early (E) and atrial (A) 
peak filling velocity, and subsequently calculation of the E/A ratio and 
the deceleration time of the E peak filling velocity (DT), for which cutoff 
criteria are defined for diastolic dysfunction classification (7). 
Fig 1. Estimation of left ventricular diastolic pressure by tissue Doppler imaging. 
Estimation of left ventricular diastolic pressure by the ratio of transmitral E (A) and 
mitral septal annular velovity (B), E/E’. The E/E’ ratio in this subject is 4, which is within 
normal limits. Courtesy of Dr Rogério Teixeira.
In contrast to the wealth of studies in LV systolic dysfunction, there is 
relative inexperience in cardiac MR assessment of diastolic LV function. 
Nonetheless, a number of MR techniques have been used to evaluate 
diastolic function. Phase-contrast MR imaging with velocity encoding 
offers an attractive alternative for the assessment of the transmitral flow 
A B
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velocity. From a time-resolved phase-contrast acquisition with velocity 
encoding perpendicular to the mitral plane (Figure 2), a time-velocity 
curve representing the transmitral in- flow is obtained. Similar to Doppler 
echo US, waveform analysis provides the assessment of the E/A ratio and 
DT. 
Fig 2. Measurement of transmitral flow. A and B) Phase-encoded MRI obtained with a 
phase-contrast sequence shows a region of interest placed at the centre of the mitral 
orifice. The transmitral flow curve is obtained from this region of interest. C) Normal 
diastolic function. The transmitral flow curve is composed of two peaks. The first one is 
the E wave and second one is the A wave. The E wave corresponds to rapid LV filling at 
early diastole; the A wave corresponds to late LV filling during end-diastole, secondary 
to LA contraction. D) Transmitral flow curve indicative of impaired myocardial 
relaxation, with a peak A superior to peak E.
With the advent of tissue Doppler imaging, quantification of longitudinal 
myocardial velocities has significantly simplified the interpretation of LV 
diastolic function. Mitral annular velocities in the longitudinal direction 
are obtained at the interventricular septum and lateral wall, and waveform 
A B
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analysis results in early (E’) and late (A’) annular velocities. E’ is affected by 
LV relaxation, preload conditions, and LV minimal pressure (7). Therefore, 
E’ and the E/E’ ratio play an important role in the estimation of LV filling 
pressures (Figure 1). Velocity-encoded MR imaging and tissue Doppler 
imaging can be used interchangeably for assessment of longitudinal 
myocardial velocities (8), with comparable values between MR imaging 
and tissue Doppler imaging for diastolic function assessment (9).
A number of novel indices of regional and global LV diastolic function 
were developed in recent years, including myocardial strain and strain rate 
imaging by echocardiography, that permits the evaluation of myocardial 
deformation and quantifies LV rotation, twist, and untwist (10, 11). For a 
better understanding of these concepts of strain and strain rate imaging, 
it is important to realize that: wall motion measurements (displacement 
and velocity) cannot differentiate between active and passive movement 
of a myocardial segment, whereas deformation analyses (strain and strain-
rate imaging) allow discrimination between active and passive myocardial 
tissue movement.  
Strain imaging can also be performed by MRI. Cardiovascular MR tagging 
remains the most widely available and validated cardiovascular MR 
modality for myocardial strain quantification. Cine displacement encoding 
with stimulated echoes (DENSE) has been proposed as a method that 
offers increased spatial resolution related to the pixel wise displacement 
encoding and more direct computation of displacement (12). Nevertheless, 
the value of improved acquisition MR imaging techniques such as the 
application of tagging and strain imaging in diastolic function testing is 
still under investigation.
1.2 Systolic dysfunction
Traditionally, the clinical standard in the assessment of global LV systolic 
function is primarily based on the quantification of LV chamber volumes 
to derive LV ejection fraction. Although quantification of systolic 
function by LV ejection fraction is easily understandable and reasonably 
reproducible, it is highly dependent in preload and afterload. Myocardial 
velocity, strain, and strain rate imaging are more sensitive systolic markers 
than LV ejection fraction. Similarly, quantification of systolic function by 
myocardial velocity strain, and strain rate imaging has been shown to be 
significantly correlated with global LV systolic function. Previous studies 
have demonstrated subclinical myocardial systolic dysfunction in diabetic 
patients using 2-dimensional speckle tracking echocardiography (13-15). 
Cine DENSE, a motion-encoding MR imaging technique for myocardial 
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strain assessment with high spatial resolution, also identified subclinical 
myocardial dysfunction in patients with DM2 (16).
2. Metabolic imaging of diabetic heart 
disease
Magnetic resonance spectroscopy (MRS) is a companion technique to the 
more familiar magnetic resonance imaging (MRI) scan. 
Cardiac 1H-MRS studies use the same hardware (i.e., magnet, gradient and 
radiofrequency coils) as any cardiac MR imaging examination.  Presently, 
MRS is technically difficult, requires lengthy scans, and specialist expertise, 
as well as additional magnetic resonance hardware and software.
Whereas MR imaging determines the spatial distribution of water (and lipid) 
protons across a region of interest, MRS measures the chemical content 
of MR-visible nuclei. The most widely studied nuclei are phosphorus 
(31P), hydrogen (1H) and to a lesser extent sodium (23Na). The advent of 
hyperpolarisation techniques has opened a new field for carbon-13 (13C)-
MRS. Each of these nuclei assesses different aspects of cardiac metabolism.
MRS is particularly advantageous for assessing metabolism because the 
chemical properties and environment of each nucleus determine the 
frequency at which it appears in the MR spectrum, giving rise to peaks 
corresponding not only to specific metabolites but also to the constituent 
nuclei of each metabolite. 
The proton is the nucleus with the highest MR sensitivity and natural 
abundance in living tissue (>99.9 %). Therefore, 1H-MRS can potentially 
become a powerful technique as it can detect and quantify a variety 
of myocardial metabolites including lipids, taurine, carnitine and total 
creatine.
Increased nutritional fatty acid intake and increased lipolysis in diabetes 
will lead to increased free fatty acid delivery to nonadipose tissues, such 
as muscle, liver, pancreas and also the heart. The metabolic effects of type 
2 diabetes mellitus on the myocardium have been previously described in 
experimental models, and include increased myocardial nonesterified fatty 
acid utilization, an increased glucose flux and subsequently triglyceride 
accumulation, and subsequent increased formation of reactive oxygen 
species. These processes, commonly referred to as “gluco-lipotoxicity,” 
contribute to decreased adenosine triphosphate synthesis, mitochondrial 
dysfunction, and finally to apoptosis of myocardial cells (17).
1H-magnetic resonance spectroscopy (1H-MRS) has proved to be a reliable 
Non-invasive imaging of cardiovascular disease in diabetes mellitus     |     23
method to noninvasively quantify cardiomyocytic triglyceride content 
in vivo (18). As the heart moves due to contraction and breathing, MRS 
is subject to motion artefacts. Therefore, ECG triggering is necessary to 
correct for motion of the heart throughout the cardiac cycle. Respiratory 
motion compensation has been performed with respirometer triggered 
acquisition, breath-hold scanning sequences, and by using navigator 
echoes (19-21). Given the location of the heart inside the body, dedicated 
localisation techniques are required to obtain the metabolite signals from 
the myocardium only. The most commonly used single-voxel techniques, 
based on either a double spin-echo method (PRESS–Point-RESolved 
Spectroscopy sequence) or stimulated echo sequence (STEAM–STimulated 
Echo Acquisition Mode sequence) (22).
The voxel for cardiac MRS is typically placed in the inter-ventricular 
septum to avoid contamination of the spectrum with signals arising from 
pericardial fat. A typical myocardial 1H MRS will display signals arising 
from water, creatine, choline, and fat. As the water signal is approximately 
100-1000 times that of the fat signal, acquisition of 1H MRS both with 
and without water suppression is essential for reliable quantification of 
intramyocardial triglyceride content. Using dedicated software, signal 
amplitudes from the intracellular triglycerides and water are quantified 
and expressed as triglyceride/water ratio.
In a large human study using 1H-MRS, McGavock et al (23) showed that 
cardiac steatosis occurs in patients with impaired glucose tolerance 
even before the onset of type 2 diabetes mellitus and precedes cardiac 
dysfunction. Another study compared patients with type 2 diabetes mellitus 
with controls of the same age and body-mass index and showed that there 
is an increase in myocardial triglyceride content in uncomplicated type 
2 diabetes mellitus and is associated with an impairment of LV diastolic 
function (24).
Over the last decade, 1H-MRS has become an invaluable technique to 
non-invasively assess cardiac lipid in clinical and pre-clinical research. 
MRS may provide insights into the early cardiac metabolic changes 
in diabetes that may lead to heart disease and help identify potential 
therapeutic targets.
However, technical challenges, limited spatial and temporal resolution 
have hampered its widespread development, especially as a clinical 
diagnostic tool. 
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3. Coronary artery disease
Compared to individuals without diabetes, those with diabetes have a 
higher prevalence of coronary artery disease, a greater extent of myocardial 
ischemia, and are more likely to have a myocardial infarction and silent 
myocardial ischemia
Various non-invasive methods are available for the non-invasive 
assessment of CAD in diabetes and their diagnostic and prognostic value 
will be discussed.
The “gold standard” for detection of CAD remains invasive angiography 
with vessel-selective contrast injection of the coronary arteries. Both spatial 
(0.2 mm) and temporal (5 ms) resolution of the technique are extremely 
high, and the degree of luminal narrowing can be quantified precisely. 
This is an invasive and expensive procedure with a small but definite risk 
for complications. Noninvasive testing is increasingly used to assess CAD, 
and multiple methods are now available. 
The various non-invasive imaging modalities available for investigation of 
CAD can be broadly divided into the categories below:
(a) Anatomical imaging, which allow direct visualisation of the coronary 
arteries:
- coronary calcium score (CAC)
- coronary computed tomography (CT) angiography using electron beam 
CT (EBCT) or multidetector CT (MDCT)
- MR angiography of the coronary arteries.
(b) Assessment of the functional significance of coronary stenosis:
- myocardial perfusion scintigraphy, which includes single photon 
emission CT (SPECT) and positron emission tomography (PET)
- stress echocardiography (SE)
- contrast echocardiography
- cardiac MR imaging including stress MR imaging and delayed 
enhancement sequences.
3.1 Anatomical imaging
There is a consensus in the literature about an increased prevalence of 
coronary atherosclerotic plaques in diabetic hearts, with such plaques 
bearing a higher propensity for rupture.
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Anatomical imaging assesses atherosclerosis by direct visualization of 
the coronary arteries. Since the coronary arteries are small, tortuous, and 
move substantially during the cardiac cycle, imaging remains technically 
challenging. As a result, all techniques have shortcomings and limitations, 
but with recent and ongoing technical advances, image quality and 
diagnostic accuracy are continuously improving. Besides noninvasive 
angiography, these techniques may also allow assessment of plaque 
composition in the near future.
In the following topics we will discuss the role of non-invasive imaging for 
the direct visualization of coronary artery disease in diabetes mellitus.
3.1.1 Coronary artery calcium scoring
Since the presence of calcium is related to the presence of atherosclerosis, 
coronary calcifications serve as a direct marker for coronary artery disease.
Coronary artery calcium (CAC) scoring used to be obtained using EBCT, 
which has now been replaced by MDCT (Figure 3). CAC is a reflection 
of an individual’s global atherosclerotic burden and is reported either 
in Agatston units (25) or by the volume scoring method, both of which 
correlate well with each other (26). The Agatston score assigns a CT factor 
to the coronary calcium based on the Hounsfield unit in all the coronary 
arteries and compiles a total score based on age and gender.
Fig 3. Measurement of coronary artery calcium scoring by MDCT. Arrrows are pointing 
to the main coronary arteries (RCA right coronary artery; LAD left anterior descending 
artery; LCX left circunflex artery). The table on the left illustrates the results obtained.
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CAC has been shown to be independently associated with cardiovascular 
morbidity and mortality (27). Furthermore, CAC has been consistently 
additive to Framingham risk score (27-31) and results in improved 
reclassification (32-34). This powerful body of literature culminated in 
the incorporation of CAC screening in the ACCF/AHA Guidelines for 
Assessment of Cardiovascular Risk in Asymptomatic Adults (35). In general, 
a calcium score of 0 is considered to rule out CAD, whereas calcium scores 
>400 represent extensive calcifications and as a consequence extensive 
CAD. Studies exploring the presence and extent of calcium between 
patients with and without diabetes mellitus showed considerably higher 
calcium scores in patients with diabetes mellitus as compared to their 
non-diabetic counterparts (36, 37). Moreover, asymptomatic patients 
with diabetes mellitus presented with similar extent of CAC as compared 
to symptomatic patients without diabetes mellitus (38). Accordingly, 
coronary calcium may be used to identify CAD non-invasively in patients 
with diabetes mellitus. 
Absence of CAC has been noted in 15%–38% of patients (39, 40). Patients 
with 0 CAC represent a very important cohort as their cardiovascular 
disease (CVD) event rate was found to be similar to patients without 
diabetes (40, 41), challenging the notion that diabetes is a CVD equivalent 
(42). Based on this extensive evidence, the ACCF/AHA recommended the 
use of CAC to risk stratify adults >40 years of age with diabetes (35).
In the general population coronary calcium score has been demonstrated 
as a strong predictor for coronary events (26-28, 43). Data on prognostic 
stratification with calcium scoring in patients with diabetes mellitus are 
presently less available. In a study by Raggi et al (41), 10,377 patients 
(903 with diabetes) were followed for a period of 5.0 ± 3.5 years after 
CAC imaging. Mortality increased with increasing baseline CAC levels 
for both diabetic and non-diabetic individuals. However, despite similar 
CAC scores, there was a greater increase in mortality in diabetic than non-
diabetic patients for every increase in CAC score
3.1.2 Coronary CT angiography
It is important to realize that although calcium strongly correlates with 
total atherosclerotic burden, it is not directly related to the degree of 
stenosis. Also, the technique is not site-specific and high grade lesions 
may be observed at sites with limited calcium, whereas extensive calcium 
can occur in the absence of significant stenosis. Accordingly, the presence 
of obstructive CAD cannot be diagnosed with this technique, and the 
strength in calcium scoring mainly lies in risk stratification based on the 
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evaluation of total atherosclerotic burden.
More detailed information on the coronary anatomy can be derived from 
noninvasive contrast-enhanced coronary CT angiography, which permits 
direct visualization of the coronary arteries (Figure 4). 
Fig 4. Coronary CT angiography scan. A) Volume rendering of the coronary tree. B) 
Curvilinear reformat of a normal right coronary artery. C) Curvilinear reformat of a 
normal left circunflex artery.  D) Curvilinear reformat of the left anterior descending 
artery showing a small, non-significant mixed plaque in the mid left anterior descending 
artery.
The accuracy of coronary CT angiography to detect significant (>50%) 
stenosis as compared to conventional coronary angiography has been 
evaluated in numerous studies. 
In the general population, the sensitivity and specificity to detect CAD 
are 91 and 96%, respectively (44). At present only two studies dedicated 
to patients with diabetes mellitus are available, showing similar values of 
accuracy for the detection of coronary stenosis as demonstrated in the 
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general population (45, 46). The advantage of this technique is the high 
negative-predictive value that approaches 100%
An interesting feature of MDCT is the fact that not only is the coronary 
lumen visualised but also the vessel wall, allowing the possibility to non-
invasively detect non-calcified plaques (Figure 5). 
Fig 5. Coronary CT angiography scan, curvilinear reformats. A) Calcified significant 
plaques (arrow) in proximal left anterior descending and first diagonal arteries. 
B) Non-signicant small non-calcified plaque in proximal right coronary artery (arrow). 
C) Mixed significat plaque (arrows) in the left anterior descending artery. D) Significant 
non-calcified plaque (arrows) in the right coronary artery.
There is a good correlation between plaque volume estimation on 
intravascular ultrasound and on CT (47). Plaque volume estimation has 
the potential for monitoring response to lipid-lowering therapy (48). 
However, it is affected by several variables including the image quality 
D
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and interobserver variability (47, 49, 50).
To a limited extent, information on plaque composition can also be 
derived. Low attenuation plaques (i.e. non-calcified plaques), plaques with 
spotty calcification (mixed plaques) and those associated with constrictive 
remodelling are more likely to result in an acute coronary syndrome (47-
50).
Using coronary CT angiography, it has been demonstrated that diabetic 
patients have more extensive, diffuse coronary atherosclerosis compared 
with matched nondiabetic patients (45, 46). 
The CONFIRM Registry, a large international multicenter study, 
strengthened the prognostic value of MDCT coronary angiography in the 
general population (51). Preliminary results suggest that CT angiography 
has incremental prognostic information over baseline clinical variables 
also in diabetic patients (52, 53). In both patients with and without diabetes 
mellitus with absence of disease, the event rate was 0% over a median 
follow-up of 20 months. The event rate increased in patients without 
diabetes mellitus but with obstructive CAD and was highest in patients 
with diabetes mellitus and obstructive CAD (53).
3.1.3 Coronary MR angiography
MR imaging has attempted to provide noninvasive images of the coronary 
arteries. While an initial report of 39 patients suggested a sensitivity and 
specificity of 90 and 92%, respectively (54), additional reports were less 
optimistic. Recent developments, including free breathing, navigator 
techniques, and three-dimensional acquisition techniques, permit 
superior visualization of the coronary arteries. In the general population, 
the sensitivity and specificity for the detection of CAD are 72 and 86%, 
respectively (28 studies, 903 patients) (55). However, up to 30% of all 
segments had to be excluded due to uninterpretability. 
Currently, despite recent developments such as free breathing and 
navigator techniques, the performance of MDCT coronary angiography is 
considered to be better than that of coronary MR angiography. Dedicated 
studies in patients with diabetes have not been published.
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3.2 Assessment of the functional significance of 
coronary stenosis
The basis of functional imaging is the detection of CAD by assessing the 
hemodynamic consequences (i.e., ischemia) of CAD rather than direct 
visualization of the coronary arteries. 
A sequence of events occurs during induction of ischemia, referred to as 
“the ischemic cascade” (56). Myocardial oxygen consumption and oxygen 
delivery determine the myocardial tissue oxygenation. Development 
of ischemia is the end result of a sequence of events resulting from an 
imbalance between myocardial oxygen consumption and myocardial 
oxygen delivery called the ischemic cascade. It refers to the temporal 
sequence of pathophysiological events that occurs within seconds of 
occlusion of a coronary artery. Early (within seconds) in the ischemic 
cascade, perfusion abnormalities occur, and systolic wall motion 
abnormalities follow within 10–20 s. Electrocardiogram (ECG) changes 
and angina occur only at the end of the cascade. 
Accordingly, exercise ECG is predictably not the most sensitive technique, 
and its diagnostic accuracy has been demonstrated to be low in patients 
with diabetes (57). Conversely, abnormalities in perfusion and systolic wall 
motion are early markers of ischemia.
The ischemic changes become irreversible after 30min, when myocardial 
necrosis sets in. It starts in the subendocardium and moves towards the 
epicardium as a wave front phenomenon. 
For ischemia assessment, imaging needs to be performed during stress 
and at rest. Comparison of the stress and rest images reveals whether 
stress-inducible perfusion or systolic wall motion abnormalities are 
present, indicating ischemia. The stress can be performed using bicycle 
or treadmill exercise or (in patients unable to exercise) pharmacological 
agents. Pharmacological stressors include dobutamine (a β1–specific 
agonist), which increases heart rate, contractility, and arterial blood 
pressure, resulting in increased myocardial oxygen demand; adenosine 
(a direct vasodilator); or dipyridamole, which act indirectly by inhibiting 
cellular uptake and breakdown of adenosine.
Adenosine has a shorter half-life than dipyridamole; in case of significant 
side effects, termination of adenosine infusion alone may suffice whereas 
with dipyridamole, reversal of drug action with aminophylline is often 
required. Dobutamine perfusion imaging is potentially indicated in patients 
with contraindications to dipyridamole and adenosine (obstructive 
pulmonary disease, heart block). 
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The presence of myocardial perfusion defects during stress is due to 
heterogeneous flow distribution because of 2 potential mechanisms: 
obstructive epicardial coronary artery disease due to atherosclerosis and 
subsequently reduced flow during stress (58); or insufficient vasomotor 
response in the coronary microvasculature due to endothelial dysfunction 
resulting in relative hypoperfusion during stress (59).
Functional imaging performed using gated SPECT, (contrast) stress 
echocardiography and MR imaging allow integrated assessment of 
perfusion and function at rest and after stress.
It is important to realize that the predictive value of these functional 
tests is not only defined by their sensitivity and specificity but also by the 
prevalence of disease in the investigated population. The incremental 
value of non-invasive stress testing is largest when the pre-test likelihood 
is intermediate because the test result is likely to have the largest effect 
on the post-test probability of CAD and hence on clinical decision making. 
Some authors have proposed the use of clinical scoring in diabetes mellitus 
to select patients with intermediate risk for further testing (60).
3.2.1 Myocardial perfusion imaging/nuclear imaging
Stress perfusion imaging with thallium-201, technetium-99m sestamibi or 
technetium-99m tetrafosmin detects heterogeneous flow distribution due 
to decreased coronary flow reserve during exercise or pharmacological 
vasodilatation. 
Current state of the art is ECG gated SPECT. Images are taken following 
exposure to stress and at rest, allowing the identification of fixed and 
reversible defects (Figure 7). The dimensions of the left ventricle and 
ejection fraction can also be determined.  
Fig 7. Myocardial perfusion using gated SPECT at rest and after adenosine stress. 
Resting images are depicted in the lower row. Stress images are depicted in the upper 
row. Reversible perfusion defects were observed in the anteroseptal regions (arrows). 
Courtesy of Dr Maria João Cunha.
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Stress testing combined with nuclear imaging has a sensitivity of 86% and 
a specificity of 74% to detect significative coronary artery stenosis in the 
general population (based on pooled analysis of 79 studies, 8964 patients), 
and has a similar diagnostic accuracy among diabetics (61).
The prevalence of myocardial perfusion defects as assessed by SPECT 
myocardial perfusion imaging in asymptomatic diabetic patients ranges 
from 20% to 40% in several prospective studies (73, 74), and the prognostic 
value of SPECT myocardial perfusion imaging in diabetic patients has been 
confirmed in several previous studies (62-66).
A 5-year follow-up of the DIAD study (67) found that SPECT myocardial 
perfusion imaging provides good risk stratification, with a 6-fold higher 
risk of cardiac death/nonfatal myocardial infarction in patients with 
moderate to large defects versus no or small defects (2.4% vs. 0.4%, 
P<0.001). However, it does not appear that this information leads to 
improved clinical care because there was no significant decrease in 
cardiac death/nonfatal myocardial infarction in asymptomatic diabetic 
individuals screened for ischemia versus routine clinical care (67). One 
possible explanation for a lack of screening benefit is the lower risk of this 
population given that patients with known CAD were excluded. It is also 
possible that increased use of evidence-based medical therapy in both 
the screened and unscreened groups minimized the differences between 
them.
Despite the prognostic benefit of SPECT myocardial perfusion imaging, 
the rate of cardiac events is unacceptably high in diabetic patients with 
normal myocardial perfusion (68), up to 14% in diabetic men. This high 
rate is likely secondary to both false-negative studies for significant CAD 
by SPECT myocardial perfusion imaging and to the increased prevalence 
of mild stenosis with a higher risk of plaque rupture. 
SPECT perfusion studies in some patients with three-vessel or left main 
CAD can appear normal with uniform tracer uptake due to balanced 
ischemia. In this situation, flow reserve is reduced in all three coronary 
supply regions yielding no focal defects. Similarly, some patients with 
diffuse endothelial and/or microvascular dysfunction causing symptoms 
can show homogenous tracer distribution on post-stress scans. This may 
be why the annual cardiac death or nonfatal myocardial infarction rate in 
rather high in diabetic patients with normal SPECT perfusion studies. 
Positron Emission Tomography myocardial perfusion imaging can 
overcome these limitations of SPECT perfusion imaging.
PET consists of perfusion imaging with a perfusion tracer (rubidium-82, 
nitrogen-13 ammonia or oxygen-15 water) and functional metabolic 
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imaging with 18F- fluorodeoxyglucose (FDG).
Mismatch between flow and metabolism, i.e. reduced flow with normal or 
increased FDG uptake, suggests reversible ischemia. Matched reduction 
in blood flow and metabolism suggests an infarct.
PET myocardial perfusion imaging has been applied in research to examine 
coronary microvascular reactivity, in which absolute blood flow and 
myocardial flow reserve can be accurately measured using tracer kinetic 
models and dynamic imaging. This is, in part, due to the high temporal 
resolution and attenuation correction inherent in PET technology (69). 
At present no specific PET imaging studies have addressed the diagnostic 
and prognostic value of cardiac PET imaging stress testing in a diabetic 
population.
Another active field of research is the detection of vulnerable coronary 
plaques with PET-CT. Studies have already shown the usefulness of FDG 
PET-CT as a marker of vascular inflammation and macrophage burden (70, 
71). A recently published study using PET-CT with the tracer 18F-sodium 
fluoride could identify ruptured and high-risk atherosclerotic plaques in 
patients with symptomatic coronary artery disease (72).
Future studies are needed to demonstrate the diagnostic accuracy of 
these techniques and investigate their risk/benefit ratio.
3.2.2 Stress echocardiography
Echocardiographic evaluation typically focuses on functional changes 
due to coronary artery narrowing or occlusion - specifically systolic 
wall thickening and endocardial motion. Both physical exercise and 
pharmacological stress can be used. Resting wall motion abnormalities 
mainly represent infarcted myocardium. Stress-induced new or worsening 
regional or global wall motion abnormality is a reliable predictor of 
ischemia.
The accuracy of stress echocardiography is dependent on the degree of 
stenosis, the amount of myocardium at risk and the degree of induced 
wall motion abnormality (73). False-negative results are more likely with 
submaximal exercise (in the case of exercise-induced stress), single-vessel 
disease and moderate stenosis (50– 70%).
Stress echocardiography has a mean sensitivity of 86% and a specificity of 
81% in the general population (74).
There are limited data that specifically address the utility of stress 
echocardiography in patients with diabetes mellitus. Hennessy et al 
34     |     Chapter II
(75) evaluated 52 patients with diabetes mellitus referred for cardiac 
assessment using dobutamine stress echocardiography (DSE). Sensitivity, 
specificity, and positive and negative predictive values of DSE for significant 
CAD detection were 82%, 54%, 84%, and 50%, respectively. Although the 
study was limited by the small size of the cohort, it demonstrated similar 
diagnostic accuracy for DSE in a diabetic population. 
Another small study compared several forms of non-invasive stress testing 
in 56 asymptomatic diabetic patients, demonstrating a positive predictive 
value of 60% for exercise ECG, 69% for DSE, and 75% for myocardial 
perfusion imaging (76).
A negative stress echocardiography study confers a 0.5–0.8% risk of 
cardiac death or non-fatal myocardial infarction (77). An abnormal stress 
echocardiography study is associated with an increased risk of adverse 
cardiac events. The risk is increased with resting left ventricular dysfunction, 
extensive ischemia and extensive wall motion abnormality (78).
The prognostic value of stress echocardiography among diabetic patients 
has been evaluated in several larger studies. Either pharmacological or 
exercise echocardiography was applied in diabetic patients with cardiac 
symptoms. The prevalence of abnormal studies ranged from 40-60% (79). 
In 2012, van der Sijde et al (80) studied the prognostic value of DSE in 396 
diabetic patients during a mean time of 13 years. DSE provided incremental 
value over clinical characteristics and stress test parameters for prediction 
of mortality and cardiac events. Survival analysis showed that DSE 
provided optimal risk stratification up to 7 years after initial testing; after 
that period, the risk of adverse outcome increased comparably in both 
normal and abnormal DSE patients.
3.2.3 Myocardial contrast echocardiography
With recent developments in echocardiographic equipment and 
microbubble contrast agents, real time perfusion imaging of the 
myocardium is now feasible. The rate of replenishment within the 
myocardium is dependent on the presence of intact microvasculature and 
myocardial blood flow rate, and the intensity at which the contrast effect 
plateaus is dependent on myocardial blood volume. 
This technique is promising because a perfusion abnormality would 
be expected to occur before a regional wall motion abnormality in the 
ischemic cascade. However, at present its use is limited to a few centers 
only and further standardization of the methodology is required before 
the technique is established (81).
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3.2.4 Magnetic resonance perfusion imaging and 
dobutamine stress imaging
Magnetic resonance imaging combines superb image quality and 
the advantage of conducting myocardial perfusion and wall motion 
measurements at rest and under stress conditions during a single session 
examination. For perfusion imaging with MRI, adenosine is the first choice 
agent. For the detection of wall motion abnormalities both adenosine and 
dobutamine can be administered as a stressor. MRI offers the assessment 
of first pass myocardial perfusion with high spatial resolution of 2-3 mm, 
which even permits differentiation of transmural and sub-endocardial 
perfusion defects (Figure 8). 
Fig 8. Myocardial perfusion imaging by MRI during the first pass of an intravenously 
injected contrast bolus. Rest image (A) shows a small subendocardial defect in the 
infero-septal wall. In the stress image (B) there is a large subendocardial perfusion 
defect in the inferior, septal and infero-lateral wall (arrows), confirming the presence 
of acute ischemia. 
Many publications have shown that MR myocardial perfusion imaging 
has similar or superior diagnostic accuracy to the more established 
nuclear techniques for myocardial perfusion imaging (82-84). Studies 
that combine MR myocardial perfusion and delayed enhancement 
imaging have demonstrated significant improvements in the overall 
diagnostic performance of this technique for the detection of CAD (82-
85). The recent Clinical Evaluation of Magnetic Resonance Imaging in 
Coronary Heart Disease (CE-MARC) (86) trial employed a multiparametric 
MRI protocol (consisted of rest and adenosine stress perfusion, cine 
imaging, late gadolinium enhancement, and MR coronary angiography) 
and demonstrated superior sensitivity and negative predictive value  vs 
A B
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myocardial perfusion scintigraphy (86% and 90% vs 66% and 79%, 
respectively) for the diagnosis of coronary artery disease. 
A recent meta-analysis confirmed a high sensitivity of 89% and a moderate 
specificity of 80% for the diagnosis of significant CAD in a population with 
a high prevalence of CAD of 57% (87). The value of stress MR imaging 
in low-prevalence populations is not clear. False positive tests can be 
attributed to the presence of artefacts due to susceptibility (called dark 
rim artefacts), poor gating and motion artefacts (82-85, 88).
An abnormal adenosine stress MR imaging was associated with an 
increased risk of a cardiac event, and an abnormal dobutamine stress 
perfusion was associated with a high risk of a cardiac event over a follow 
up period of 2.3 years (89).
Furthermore, a negative MR myocardial perfusion study seems to be 
associated with an excellent long-term prognosis. Several studies have 
emphasised the high negative predictive value of MR myocardial perfusion 
imaging for event-free survival (89-91).
In addition to first-pass perfusion stress imaging, MRI can be used to 
detect and quantify abnormalities of myocardial wall motion following 
the administration of dobutamine, similar to stress echocardiography. 
MRI has the inherent advantage over echocardiography of higher spatial 
resolution, good tissue contrast and higher reproducibility (92).
The object of this study is to induce reversible myocardial ischemia by the 
action of positive inotropic and chronotropic agents.
Using high, incremental doses of dobutamine, it is possible to diagnose 
coronary artery disease by the depiction of new stress-induced wall-
motion abnormalities that were not present in the rest scans.
The same principle is used in the evaluation of myocardial viability, but 
with a low-dose dobutamine stress test. Myocardium that is viable but 
functionally abnormal shows a brief improvement in contractility in 
response to positive inotropic pharmacologic stimulus. 
High–dose stress dobutamine MRI as demonstrated good sensitivities 
(83–96%) and specificities (80–100%) for detection of significant CAD (93).
At present no specific MR imaging studies have addressed the diagnostic 
and prognostic value of cardiac MR imaging stress testing in a diabetic 
population.
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3.2.5 Delayed enhancement MRI
Myocardial fibrosis is a frequent occurrence in patients with diabetes 
mellitus and one of the major factors predisposing to the development 
of heart failure. Cardiac fibrosis is the consequence of extracellular cardiac 
matrix remodeling. Previous studies have also demonstrated histological 
evidence of increased diffuse microscopic fibrosis in the myocardium of 
diabetic patients (94, 95).
Currently, MR imaging with delayed contrast enhancement is the gold 
standard for noninvasive visualization of myocardial fibrosis (96). This 
technique is based on an inversion recovery pulse sequence and delayed 
imaging of the heart at approximately 10-20 minutes after administration 
of gadolinium-based contrast agents. Due to the chemical charge and 
molecular size of these gadolinium-based contrast agents, they rapidly 
diffuse from the intravascular to extracellular space, but do not enter the 
intracellular space. Consequently, contrast accumulates within infarcted 
or scarred myocardial tissues. By selecting an appropriate inversion time to 
“null” normal myocardium, scar tissue will appear as bright hyperenhanced 
regions (Figure 6) (97).
Fig 6. Delayed-enhancement MRI study. A) Four-chamber image showing difuse 
subendocardial enhancement in the left ventricular myocardium (arrows), from 
coronary artery disease. B) Short-axis image showing transmural enhancement in the 
left ventricular inferior wall (arrows), from myocardial infarction. 
Different from replacement fibrosis, where regional collagen deposits 
appear in areas of myocyte injury, delayed enhancement has a limited 
sensitivity for interstitial diffuse fibrosis (97, 98). Therefore, to image 
diffuse interstitial fibrosis within the myocardium other techniques might 
be more suitable.
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While echocardiogram backscatter techniques may be applied for that 
purpose (99), myocardial tissue characterization is definitely an area where 
MR imaging plays a large role.
In MR imaging, gadolinium-based contrast agents accumulate and have 
increased washout times within these myocardial fibrous tissues because 
of the absence of viable myocytes and an increased volume of distribution. 
By directly quantifying T1 values for each voxel in the myocardium, a 
parametric map can be generated representing the T1 relaxation times of 
any region of the heart.
Contrast-enhanced myocardial T1 mapping may noninvasively quantify 
diffuse interstitial myocardial fibrosis in diabetic patients. A shorter global 
contrast-enhanced myocardial T1 time (suggestive of a higher burden of 
interstitial myocardial fibrosis) may be present in diabetic patients and 
relate to myocardial dysfunction (100). 
Future studies are needed to evaluate the prognostic relevance of 
myocardial fibrosis detection by late gadolinium enhancement or T1 
mapping in diabetes mellitus.
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4. Cardiac autonomic neuropathy
In clinical practice cardiac autonomic neuropathy (CAN) was diagnosed 
based on a battery of autonomic tests that mostly depend on the heart 
rate variability and its response to various stimuli that affect the autonomic 
nervous system.
There is evidence to suggest that scintigraphic assessment is more sensitive 
in detecting cardiac autonomic neuropathy that indirect autonomic 
reflex testing, because MIBG uptake is reduced in patients with normal 
autonomic tests (101, 102).
SPECT and PET imaging are available for the assessment of cardiac 
sympathetic adrenergic innervation and activation. Essentially, adrenergic 
nerve imaging is based on 2 principles: synthesis of false neurotransmitters 
(catecholamine analogs) or the labeling of true adrenergic 
neurotransmitters. Both techniques allow evaluation of abnormalities in 
cardiac sympathetic innervation by visualizing the uptake and storage of 
radiolabeled neurotransmitters transported into the presynaptic nerve 
terminals.
Abnormalities in sympathetic innervation can be assessed using 123-iodine 
meta-iodobenzylguanidine (123I MIBG), a norepinephrine analog that is 
taken up and accumulated in the presynaptic nerve terminals. Currently, 
123I MIBG represents the most commonly used tracer in clinical cardiology 
to evaluate cardiac sympathetic innervation patterns. Planar and 
tomographic SPECT images are acquired 10-20 minutes (early) or 3-4 hours 
(late) after MIBG administration. From the planar images, semiquantitative 
measurements, such as heart-to-mediastinum ratio and cardiac washout 
rate, are used to evaluate global sympathetic innervation. SPECT images 
are used to assess regional abnormalities in sympathetic innervation.
Diabetic patients with CAN show a decreased myocardial uptake of this 
tracer, which has been independently correlated with the occurrence 
of cardiovascular events on long-term follow-up (102). In patients with 
diabetes mellitus, CAN was associated with a threefold increase in the 
progression of heart failure over a 2-year period (103).
Nevertheless, no standardized methodology or normative values exist, 
and available data on reproducibility are limited. Scintigraphic studies are 
appropriate to explore the effects of sympathetic dysfunction on cardiac 
metabolism and function and are useful in assessing cardiac sympathetic 
function in research studies (101-104).
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5. Diabetes and cerebrovascular disease
Cerebrovascular disease is a leading cause of morbidity and mortality in 
diabetes. Compared with non-diabetic patients, diabetic patients have 
at least twice the risk for stroke, earlier onset of symptoms, and worse 
functional outcomes (105, 106). Approximately 20% of diabetic patients 
will die from stroke, making it one of the leading causes of death in this 
population. Diabetic patients more often develop ischemic strokes and 
have an increased proportion of lacunar strokes that may be clinically 
silent. Allied to this, diabetes increases the risk of stroke-related dementia.
The pathogenesis of cerebrovascular disease in diabetes may include: 
accelerated atherosclerosis, autonomic neuropathy, atrial fibrillation 
and microvascular disease in deep penetrating branches of the cerebral 
arteries (105, 106).
The relation between stroke and carotid atherosclerosis is established. 
The majority of cerebral ischemic events are caused by atherosclerotic 
diseases, with most changes affecting the carotid bifurcation. This can 
occur via embolic transformation of an atherosclerotic lesion or secondary 
to ischemia caused by flow-limiting carotid artery stenosis (107). 
It has been reported that extracranial carotid atherosclerosis with the 
resulting atherothromboembolism may account for up to 20% of ischemic 
strokes (108). In patients with asymptomatic carotid artery stenosis > 60%, 
the risk of stroke is 1–2% per year (109). This makes the degree of carotid 
artery stenosis on of the most important factor in determining the risk of 
stroke (107).
Besides luminal stenosis, plaque composition and morphology are key 
determinants of the likelihood that a plaque will cause cardiovascular 
events. Diabetic patients seem to be at exceptionally high risk for the 
development of vulnerable plaques (110). 
High-frequency ultrasound transducers produce the high spatial resolution 
required to measure intima-media thickness (IMT) in vessel walls, the 
region that will show thickening with atherosclerotic plaque (Figure 9). 
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Fig 9. Carotid ultrasound studies of 2 asymptomatic subjects with type 2 diabetes 
mellitus. A) Carotid intima-media thickness measured at the far wall of the left common 
carotid artery (between calipers) showed difuse increase of the IMT (1-1.2 mm). Non-
significant calcified plaque in the left carotid bulb (arrow). B) Mixed non-significant 
plaque in the right carotid bulb and origin of the internal carotid artery (arrows).
IMT measurements show good reproducibility (111). IMT is increased in 
type 2 diabetic patients with cardiovascular disease (111-113) and is an 
independent predictor of coronary events (113). However, the magnitude 
of its predictive value when added to other risk factors is questionable.
MR imaging, which has been used for evaluation of the carotid vessels, 
makes it possible not only to quantify the size of the atherosclerotic plaque 
but also to assess intraplaque hemorrhage and the integrity of the fibrous 
cap (114). 
It is technically possible to combine magnetic resonance angiography 
(quantification of degree of stenosis and its spatial distribution) with 
high-resolution MRI imaging (characterization of the arterial wall and the 
composition of plaque).
Nevertheless, detailed characterization of plaque, including the 
identification of high-risk features, remains difficult at present. Although 
much is expected from current developments, evidently more data are 
needed before plaque characterization with MR imaging may be used 
clinically for the identification and management of patients at risk (114, 
115). No specific studies have been performed in diabetes.
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6. Diabetes and peripheral artery disease
Diabetic patients are at high risk for peripheral arterial disease.
The complex pathophysiology of diabetic foot lesions results from a number 
of factors present in the diabetic population that leads to foot pathology in 
a synergistic fashion. These factors include peripheral neuropathy, which 
leads to structural and sensory changes within the foot; microvascular 
changes, nonocclusive changes in the microcirculation leading to the 
impairment of normal cellular exchange; infection, often aggressive and 
polymicrobial and atherosclerosis of the peripheral arteries (116). 
In diabetes mellitus, peripheral artery disease begins earlier, progresses 
more rapidly and is more commonly asymptomatic. Regarding distribution 
of the disease, distal arterial involvement of the tibial and peroneal arteries 
is the predominant pattern (117). 
Patients with peripheral artery disease may be asymptomatic or may 
develop symptoms of intermittent claudication or symptoms of critical 
limb ischaemia, characterized by pain in the peripheries at rest, ischemic 
ulceration or gangrene. In diabetic patients, the combination of lower 
extremity neuropathy and ischemia secondary to atherosclerosis can 
lead to pressure necrosis, ulceration, and microbial infection. The clinical 
features are aggravated because of the decreased ability to fight infection 
by delaying or preventing delivery of oxygen, nutrients, components of a 
proper immune response, and antibiotics to the injured and infected area 
(116-118).
Noninvasive testing can be performed by peripheral Doppler 
ultrasonography, color duplex scanning, ankle-brachial pressure index 
measurement, plethysmography, transcutaneous oximetry, computed 
tomography and magnetic resonance angiography (116-118).
The results of revascularization procedures for proximal lesions are similar 
to those in non-diabetic patients, but results in distal bypasses are poor in 
the long term. Amputation rates after revascularization are much higher 
in diabetic than in non-diabetic patients (116-118). 
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Introduction
In the present chapter we will discuss the issue of screening cardiovascular 
disease in asymptomatic diabetic patients. We will first address possible 
role of imaging in assessing CAD in asymptomatic diabetes mellitus. Then, 
we will discuss the issue of myocardial functional evaluation in subclinical 
cardiovascular diabetes mellitus.
1. Coronary artery disease in asymptomatic 
diabetes mellitus
The issue of screening for coronary artery disease (CAD) in asymptomatic 
diabetic patients has been raised and debated intensively. 
Nevertheless, there are no strong data to support a benefit of screening 
asymptomatic patients with type 2 diabetes for silent myocardial ischemia.
In the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study (1), 
1123 asymptomatic diabetic patients were randomized to be screened 
with adenosine-stress radionuclide myocardial perfusion imaging or no 
screening. The primary endpoint was the occurrence of death or nonfatal 
myocardial infarction at follow-up. All patients received aggressive 
preventative therapies. The study failed to show any benefit in terms 
of the primary endpoint or for any secondary endpoints in the actively 
screened group as compared to conventional management with a 
cumulative composite of death or myocardial infarction in the range of 3% 
in both groups after a median follow-up of 5 years. Authors conclude by 
emphasizing that this is not a negative study, rather it conveys the positive 
message that diabetic patients have a fairly good outcome with state-of-
art medications when managed in a conventional manner.
To be effective, screening of asymptomatic patients must provide 
prognostic information that allows risk stratification, which then triggers 
more effective risk reduction.
Clinically, the simplest screening involves measurement of circulating 
markers (e.g. low-density lipoprotein, glycosylated hemoglobin, etc.) or 
readily assessable clinical measures (blood pressure, neuropathy) as is 
done with the Framingham, UK Prospective Diabetes Study, and other risk 
engines. However, current risk engines do not provide consistently reliable 
information (2-4).
So, clinicians have relied on more sophisticated techniques such as coronary 
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artery calcium scoring (CAC) and myocardial perfusion scintigraphy 
imaging to detect coronary atherosclerosis and silent ischemia.
The most recent guidelines for the assessment of risk in asymptomatic 
adults endorse the use of CAC to risk stratify adults >40 years of age with 
diabetes (5). In a large study that included more than 10,000 individuals 
(903 with DM), diabetic patients had a higher CAC score and higher all-
cause mortality over an average follow-up of 5 years than non-diabetic 
patients (3.5% vs 2.0%) (6). Increasing CAC scores in this study were 
predictive of mortality in both diabetic and non-diabetic patients, and this 
relationship was stronger in diabetic patients. Perhaps more importantly, 
diabetic patients with a zero CAC score had a similar favorable prognosis 
to non-diabetic patients (6).
Use of CAC scoring for risk stratification in asymptomatic diabetic 
patients is not currently endorsed by the American Diabetes Association 
recommendations (7). However, if a strategy of testing asymptomatic 
diabetic individuals for the presence of silent ischemia is needed, pre-
selection of individuals based on calcium scores with the intent of 
performing subsequent functional imaging in the presence of a substantial 
atherosclerotic burden should be considered.
In diabetic patients without history of CAD, Anand et al (8), using a combined 
approach of CAC imaging and myocardial perfusion scintigraphy, reported 
abnormal myocardial perfusion scintigraphy findings in 18% of patients 
with an CAC between 10 and 100, in 48% of patients with an CAC between 
100 and 400 and in 71% of patients with CAC >1000, whereas no patients 
with absent or minimal CAC (score 0 to 10) showed abnormal myocardial 
perfusion scintigraphy. In addition, although only 20 cardiovascular 
events occurred in this population during a follow-up interval of 2.2 
years, no event was observed in patients with absent or minimal coronary 
calcification.
Thus, it needs to be recognized that while in intermediate risk subjects, 
a two-step risk stratification strategy of an initial coronary calcium scan, 
followed by selective myocardial perfusion scintigraphy imaging in subjects 
with high CAC scores sounds attractive and would be worth testing, there 
is no definitive evidence to support any clinical benefit of this approach. In 
contrast, based on the study by Anand et al (8), it seems conceivable that in 
asymptomatic type 2 diabetics without known CAD, a CAC score followed 
by selective ischemia evaluation for subjects with significant CAC (>10) 
should be considered to identify candidates for invasive CAD assessment 
(9). Thus, myocardial perfusion scintigraphy would be potentially useful 
for those with evidence of coronary atherosclerosis through a positive 
CAC scan or, as first line test, in those with abnormal resting ECG, in 
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agreement with recommendations of the American Diabetes Association 
(7). Asymptomatic diabetics with evidence of moderate to severe inducible 
ischemia at myocardial perfusion scintigraphy should then undergo 
invasive coronary angiography as they may benefit from revascularization.
Noninvasive coronary CT angiography and MRI have not been extensively 
studied in the asymptomatic type 2 diabetes mellitus population.
Using coronary CT angiography in asymptomatic patients remains 
controversial, primarily because of the higher radiation dose, added cost, 
and use of nephrotoxic contrast, but it has the potential to identify useful 
data beyond what is derived from CAC.
Recent advances in cardiac CT imaging technology allow for further 
reduction of the radiation dose from coronary CT angiography (10); 
available new dose-reducing techniques include prospective triggering 
(11-13), adaptive statistical iterative reconstruction (14), and high-pitch 
spiral acquisition (15). 
Magnetic resonance imaging is acquiring a growing body of evidence for 
screening asymptomatic cardiovascular disease in diabetes mellitus.  In a 
notable study by Kwong et al (16) MRI showed myocardial scar (delayed 
gadolinium enhancement) in 28% of diabetic patients who had no 
evidence of myocardial infarction by clinical history, medical records or 
by electrocardiogram. In this study, the presence of delayed gadolinium 
enhancement was a strong independent predictor of future major adverse 
cardiovascular events and death (hazard ratio of 4.13). It is important 
to identify patients with silent myocardial infarctions because their risk 
of future cardiovascular events is comparable to that of patients with 
clinically recognizable myocardial infarctions. 
The recent Clinical Evaluation of Magnetic Resonance Imaging in Coronary 
Heart Disease (CE-MARC) (17) trial employed a multiparametric MRI 
protocol and demonstrated superior sensitivity and negative predictive 
value vs myocardial perfusion scintigraphy (86% and 90% vs 66% and 
79%, respectively) for the diagnosis of coronary artery disease. The lack 
of widespread availability difficult the more widely use of MRI for the 
investigation of coronary heart disease.
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2. Myocardial dysfunction in asymptomatic 
diabetes mellitus
Diabetes mellitus is an independent risk factor for the development of heart 
failure (HF) (18, 19). The increased prevalence of CAD and hypertension 
in patients with diabetes mellitus contribute to the increased incidence 
of HF (20, 21). Furthermore, diabetic cardiomyopathy has been proposed 
as a primary myocardial disease in diabetic patients without significant 
epicardial CAD, hypertension, or valvular heart disease. This entity lead 
to gradual decline in left ventricular (LV) function with impairment in LV 
relaxation first and then followed by systolic dysfunction that may progress 
over time to congestive HF (22, 23). Therefore, before presenting with 
overt HF symptoms, diabetic patients may have long-standing subclinical 
myocardial dysfunction. Thus, early detection of diabetic heart disease 
may permit early treatment and prevention of heart failure progression 
(24).
The optimum process for identifying patients with diabetic myocardial 
dysfunction is unclear. Unfortunately, the measurement of brain natriuretic 
peptide does not seem to be a solution to screening. This marker of overt 
LV dysfunction (25) is released in response to increased transmural wall 
stress and appears to have limited efficacy for the detection of subclinical 
heart disease (26). Specifically, brain natriuretic peptide does not appear 
to be a worthwhile marker of diabetic myocardial disease (27, 28).
The most frequent finding in an asymptomatic patient with diabetic 
heart disease is diastolic dysfunction with normal left ventricular ejection 
fraction (22, 23, 28). Often, imaging is used to demonstrate LV diastolic 
and systolic dysfunction in diabetic heart disease.
Echocardiography and MRI are the 2 modalities that offer the most in this 
regard. They each have strengths and limitations that at present make 
them complementary. Echocardiography’s high temporal resolution 
makes it the modality of choice for assessing diastolic function, whereas 
MRI’s high spatial resolution permits precise evaluation of systolic function. 
Although MRI suffers from limited availability, and contraindications such 
as implantable metallic devices, its ability to obtain accurate information 
in patients with poor echocardiographic windows makes it an important 
alternative in the diagnosis and characterization of heart failure. Advances 
in MRI sequences increasingly allow characterization of diastole.
Factors causing LV filling pressure to rise will also cause left atrial (LA) 
pressure overload and LA dilatation (29, 30). Thus, LA volume will both 
reflect the severity and duration of LV diastolic dysfunction (29, 31, 32). 
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In agreement with this, LA size has proven to be a powerful predictor of 
outcome in the general population (33) and in several disease entities, 
including myocardial infarction, severe aortic valve stenosis and heart 
failure (31, 34, 35).
A recent prospective observational follow-up study of diabetes mellitus 
patients without overt cardiovascular disease at inclusion demonstrated 
that a dilated LA was a predictor of death and major cardiovascular 
events, even after adjustment for age and hypertension, independently 
of myocardial ischemia (36). Therefore, LA volume could emerge as a 
simple and important tool for risk stratification in type 2 diabetes mellitus 
patients.
Gupta et al have used MRI, the gold standard method in cardiac imaging, 
in 1802 subjects from the general population enrolled in the Dallas Heart 
Study with a mean age of 40 years (37). They correctly evaluated not only 
the prognostic value of LA volume and function, but also the interaction 
of each one with LV parameters and with two specific cardiac biomarkers, 
cardiac troponin T and N-terminal pro brain natriuretic peptide.
New imaging echo-based methods, in particular the most recent speckle 
tracking methods, are quicker, cheaper, and easier than MRI; however, their 
use in large outcome studies is hindered by the risk of low quality images, 
noise, and the lack of agreed common standards for this technique. Thus, 
to date, the study of LA function by ‘classic’ volumetric methods is the 
simplest, clinically applicable, and most representative of the interaction 
between dimensions and function (38).
LA dimensions and function are the consequence of what happens in 
other cardiac chambers, the left ventricle in particular. They are good 
markers of generalized cardiac dysfunction, potentially allowing for early 
detection and for an estimate of its duration. Accordingly, the study of 
Gupta et al shows that the contribution of LA variables (LA ejection fraction 
in particular) provided a significant but small increment in discrimination 
of all-cause mortality (37). Whether LA dimensions and function can also 
be therapeutic targets and not only markers of risk is a largely unexplored 
area and deserves future research.
The prognostic implications of these changes in LV and LA function and 
recommendations on systematic imaging surveillance of asymptomatic 
subjects with diabetes mellitus need further prospective evaluation.
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Highlights
Asymptomatic diabetic adults with subclinical cardiovascular disease 
represent a group at high risk for cardiovascular morbidity and mortality. 
While risk factor scoring systems such as the Frammingham risk score 
are useful in the general population, they may not be as predictive in 
diabetics as compared with the general population. CAC scoring, however, 
is consistently additive and helps positively reclassify patients and is 
therefore recommended in this population. Myocardial perfusion imaging 
remains controversial but may have a role in patients with higher CAC 
scores. Although scintigraphy has been the most widely used technique to 
study myocardial perfusion, it is accepted that MRI, being a more accurate 
method without radiation may play a greater role in the near future.
Myocardial dysfunction in diabetes mellitus is characterized predominantly 
by diastolic dysfunction consisting of relaxation abnormalities that are 
prevalent and have prognostic importance. Echocardiography and MRI 
could provide important data for risk stratification by studying subclinical 
left ventricular and left atrial dysfunction.
Cardiac imaging in asymptomatic diabetes mellitus     |     63
References
1. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et 
al. Cardiac outcomes after screening for asymptomatic coronary artery 
disease in patients with type 2 diabetes: the DIAD study: a randomized 
controlled trial. JAMA. 2009;301(15):1547-55.
2. Bansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, et al. 
Five-year outcomes in high-risk participants in the Detection of Ischemia 
in Asymptomatic Diabetics (DIAD) study: a post hoc analysis. Diabetes 
Care. 2011;34(1):204-9.
3. van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, and Dekker 
JM. Prediction of coronary heart disease risk in a general, pre-diabetic, 
and diabetic population during 10 years of follow-up: accuracy of the 
Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes 
Care. 2009;32(11):2094-8.
4. Coleman RL, Stevens RJ, Retnakaran R, and Holman RR. Framingham, 
SCORE, and DECODE risk equations do not provide reliable cardiovascular 
risk estimates in type 2 diabetes. Diabetes Care. 2007;30(5):1292-3.
5. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, 
et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in 
asymptomatic adults: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. 
J Am Coll Cardiol. 2010;56(25):e50-103.
6. Raggi P, Shaw LJ, Berman DS, and Callister TQ. Prognostic value of 
coronary artery calcium screening in subjects with and without diabetes. 
J Am Coll Cardiol. 2004;43(9):1663-9.
7. American Diabetes Association. Standards of medical care in 
diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11-66.
8. Anand DV, Lim E, Lahiri A, and Bax JJ. The role of non-invasive imaging 
in the risk stratification of asymptomatic diabetic subjects. Eur Heart J. 
2006;27(8):905-12.
9. Scholte AJ, Bax JJ, and Wackers FJ. Screening of asymptomatic patients 
with type 2 diabetes mellitus for silent coronary artery disease: combined 
use of stress myocardial perfusion imaging and coronary calcium scoring. 
J Nucl Cardiol. 2006. p. 11-8.
10. Gerber TC, Kantor B, and McCollough CH. Radiation dose and safety in 
cardiac computed tomography. Cardiol Clin. 2009;27(4):665-77.
64     |     Chapter III
11. Stolzmann P, Leschka S, Scheffel H, Krauss T, Desbiolles L, Plass A, 
et al. Dual-source CT in step-and-shoot mode: noninvasive coronary 
angiography with low radiation dose. Radiology. 2008;249(1):71-80.
12. Husmann L, Valenta I, Gaemperli O, Adda O, Treyer V, Wyss CA, et al. 
Feasibility of low-dose coronary CT angiography: first experience with 
prospective ECG-gating. Eur Heart J. 2008;29(2):191-7.
13. Earls JP, Berman EL, Urban BA, Curry CA, Lane JL, Jennings RS, et 
al. Prospectively gated transverse coronary CT angiography versus 
retrospectively gated helical technique: improved image quality and 
reduced radiation dose. Radiology. 2008;246(3):742-53.
14. Heilbron BG, and Leipsic J. Submillisievert coronary computed 
tomography angiography using adaptive statistical iterative reconstruction 
- a new reality. Can J Cardiol. 2010;26(1):35-6.
15. Achenbach S, Marwan M, Ropers D, Schepis T, Pflederer T, Anders K, et 
al. Coronary computed tomography angiography with a consistent dose 
below 1 mSv using prospectively electrocardiogram-triggered high-pitch 
spiral acquisition. Eur Heart J. 2010;31(3):340-6.
16. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence 
and prognostic implication of unrecognized myocardial scar characterized 
by cardiac magnetic resonance in diabetic patients without clinical 
evidence of myocardial infarction. Circulation. 2008;118(10):1011-20.
17. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, 
et al. Cardiovascular magnetic resonance and single-photon emission 
computed tomography for diagnosis of coronary heart disease (CE-MARC): 
a prospective trial. Lancet. 2012;379(9814):453-60.
18. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, 
et al. Association of glycaemia with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 35): prospective observational 
study. BMJ. 2000;321(7258):405-12.
19. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman 
DW, et al. Predictors of congestive heart failure in the elderly: the 
Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628-37.
20. van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, and 
Whooley MA. Diabetes, glycemic control, and new-onset heart failure in 
patients with stable coronary artery disease: data from the heart and soul 
study. Diabetes Care. 2010;33(9):2084-9.
Cardiac imaging in asymptomatic diabetes mellitus     |     65
21. Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, et al. 
Separate and joint effects of systemic hypertension and diabetes mellitus 
on left ventricular structure and function in American Indians (the Strong 
Heart Study). Am J Cardiol. 2001;87(11):1260-5.
22. von Bibra H, and St John Sutton M. Diastolic dysfunction in diabetes 
and the metabolic syndrome: promising potential for diagnosis and 
prognosis. Diabetologia. 2010;53(6):1033-45.
23. From AM, Scott CG, and Chen HH. The development of heart failure 
in patients with diabetes mellitus and pre-clinical diastolic dysfunction a 
population-based study. J Am Coll Cardiol. 2010;55(4):300-5.
24. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 
ACCF/AHA guideline for the management of heart failure: a report of the 
American College of Cardiology Foundation/American Heart Association 
Task Force on practice guidelines. Circulation. 2013;128(16):e240-319.
25. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg 
PG, et al. B-type natriuretic peptide and clinical judgment in emergency 
diagnosis of heart failure: analysis from Breathing Not Properly (BNP) 
Multinational Study. Circulation. 2002;106(4):416-22.
26. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart 
failure: good to go in 2004? J Am Coll Cardiol. 2004;44(4):740-9.
27. Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N, et al. 
The BNP assay does not identify mild left ventricular diastolic dysfunction 
in asymptomatic diabetic patients. Eur J Echocardiogr. 2006;7(1):40-4.
28. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, and 
Marwick TH. Screening for heart disease in diabetic subjects. Am Heart J. 
2005;149(2):349-54.
29. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, and Seward JB. Left atrial 
volume as a morphophysiologic expression of left ventricular diastolic 
dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 
2002;90(12):1284-9.
30. Hurrell DG, Nishimura RA, Ilstrup DM, and Appleton CP. Utility of 
preload alteration in assessment of left ventricular filling pressure by 
Doppler echocardiography: a simultaneous catheterization and Doppler 
echocardiographic study. J Am Coll Cardiol. 1997;30(2):459-67.
31. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, et al. Left 
atrial volume: a powerful predictor of survival after acute myocardial 
infarction. Circulation. 2003;107(17):2207-12.
66     |     Chapter III
32. Møller JE, Pellikka PA, Hillis GS, and Oh JK. Prognostic importance of 
diastolic function and filling pressure in patients with acute myocardial 
infarction. Circulation. 2006;114(5):438-44.
33. Ambale-Venkatesh B, Armstrong AC, Liu CY, Donekal S, Yoneyama K, Wu 
CO, et al. Diastolic function assessed from tagged MRI predicts heart failure 
and atrial fibrillation over an 8-year follow-up period: the multi-ethnic 
study of atherosclerosis. Eur Heart J Cardiovasc Imaging. 2014;15(4):442-9.
34. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, et al. Left atrial 
remodelling in patients with myocardial infarction complicated by heart 
failure, left ventricular dysfunction, or both: the VALIANT Echo study. Eur 
Heart J. 2009;30(1):56-65.
35. Dahl JS, Videbæk L, Poulsen MK, Pellikka PA, Veien K, Andersen LI, 
et al. Noninvasive assessment of filling pressure and left atrial pressure 
overload in severe aortic valve stenosis: relation to ventricular remodeling 
and clinical outcome after aortic valve replacement. J Thorac Cardiovasc 
Surg. 2011;142(3):e77-83.
36. Poulsen MK, Dahl JS, Henriksen JE, Hey TM, Høilund-Carlsen PF, Beck-
Nielsen H, and Møller JE. Left atrial volume index: relation to long-term 
clinical outcome in type 2 diabetes. J Am Coll Cardiol. 2013;62(25):2416-
21.
37. Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, et 
al. Left atrial structure and function and clinical outcomes in the general 
population. Eur Heart J. 2013;34(4):278-85.
38. Staszewsky L, and Latini R. What is the atrium trying to tell us? Eur Heart 
J. 2013. p. 255-7.
Part        II
Personal 
contribution
68     |     Personal contribution
Introduction
1. Background
Diabetes mellitus is responsible for diverse cardiovascular complications 
such as increased atherosclerosis in large arteries (carotids, aorta, and 
femoral arteries) and increased coronary atherosclerosis. Coronary 
microvascular disease may contribute to cardiac pathology as well. 
Diabetes mellitus also can affect cardiac structure and function in the 
absence of changes in blood pressure and coronary artery disease, a 
condition called diabetic cardiomyopathy.
Due to the often masked symptoms of type 2 diabetes mellitus, the disease 
may only be diagnosed several years after onset when complications have 
already occurred. Often, the prognosis of patients with type 2 diabetes 
mellitus depends on the presence of cardiovascular disease.
Research on cardiovascular complications of diabetes mellitus will allow 
the development of appropriate markers and diagnostic techniques to 
identify individuals at risk, stage the disease, prognosticate, and evaluate 
therapy relevant to the cardiovascular complications of diabetes mellitus. 
The criteria for the selection of those asymptomatic patients with type 
2 diabetes that should undergo cardiac screening and the therapeutic 
consequences of screening remain controversial. Non-invasive techniques 
as markers of atherosclerosis and myocardial ischemia may aid risk 
stratification and the implementation of tailored therapy for the patient 
with type 2 diabetes mellitus.
A number of noninvasive tests are now available to detect coronary 
atherosclerotic disease and myocardial dysfunction.
Regarding the evaluation of coronary atherosclerotic disease, CT can 
non-invasively detect the presence and extent of calcified plaque in the 
coronary arteries (coronary artery calcium score – CAC).
Observational studies revealed that diabetic patients have significantly 
higher CAC than nondiabetic patients (1-4). However, in asymptomatic 
type 2 diabetic patients, few studies have investigated the association of 
CAC with other traditional risk factors of coronary artery disease.
Regarding the evaluation of myocardial dysfunction, cardiac magnetic 
resonance has been widely accepted as the “gold standard” for the 
assessment of cardiac structure and function. 
Nevertheless, the use of cardiac MRI for the assessment of left ventricular 
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diastolic function and left atrial function is still a novelty. 
So far, none MRI-based studies of left ventricular diastolic function have 
been carried out in healthy adult individuals.
The evaluation of left ventricular diastolic function is important in type 
2 diabetes mellitus, since it represents one of the earliest preclinical 
manifestations of left ventricular dysfunction in this condition (5-10).
Additionally, although is known that the suggested mechanisms 
conducting to left ventricular dysfunction in type 2 diabetes mellitus 
include systemic phenomena that can also impact the function of the left 
atrium, there are limited published data on left atrial involvement in this 
condition.
Coronary artery disease is commonly cited as a mechanism underlying 
diastolic dysfunction (11). But there are limited and controversial published 
data on the relationship of CAC to left ventricular diastolic function (12-
14).
2. Objectives
The purpose of the present thesis is to study the role of novel cardiac 
imaging techniques in assessing cardiovascular disease in patients with 
type 2 diabetes mellitus.
Primary objectives:
1. To study the extent of CT-derived anatomic and MR-derived functional 
measures of cardiovascular disease in an asymptomatic diabetic 
population. To evaluate the relation between these CT-derived and MR-
derived measures.
Secondary objectives:
2. To evaluate the prevalence of diastolic dysfunction in a normal 
population and to determine gender-specific differences for left heart 
volumes and function, using cardiac MRI
3. To assess left ventricular diastolic function in asymptomatic type 
2 diabetes mellitus with cardiac MRI, and to evaluate whether these 
parameters of LV diastolic function are related to coronary atherosclerosis.
4. To assess left atrial function in asymptomatic type 2 diabetes mellitus 
with cardiac MRI. 
5. To evaluate the prevalence and severity of CAC scores in asymptomatic 
diabetes, and explore its association with other conventional risk factors 
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of atherosclerosis
Hypotheses
A considerable number of asymptomatic patients with type 2 diabetes 
mellitus have significant cardiovascular disease, as detected by CT and 
MR.
Left ventricular diastolic dysfunction is a marker of asymptomatic type 
2 diabetes mellitus, but may be present in a significative percentage of 
apparently normal subjects. The presence of diastolic dysfunction is 
related to coronary artery calcium score.
Asymptomatic type 2 diabetic subjects will have reduced left atrial 
function, compared with normoglycemic control subjects.
Asymptomatic subjects with type 2 diabetes mellitus would show a wide 
range of CAC scores.  
3. Material and methods
Study population
Between December 2011 and December 2013, we prospectively enrolled 
73 subjects (33 women and 40 men; mean age 60.6 +/- 7.5 years) with 
DM2 enrolled based on referral to the outpatient clinical department of 
diabetology of our institution and 82 normoglycemic controls (43 women 
and 39 men; mean age 50.3 +/- 8.2 years) recruited from the community.
Subjects were included if they met the following inclusion criteria: age 
between 45-75 years, no symptoms or history of overt heart disease 
(cardiomyopathy, coronary artery disease or valvular heart disease), no 
signs or symptoms of cerebrovascular disease, no abnormal findings on 
routine clinical and physical examination and a normal ECG. 
Exclusion criteria were: LV ejection fraction (LVEF) < 55%, regional LV wall 
motion abnormalities and valvular heart diseases assessed by CMR, severe 
renal failure, claustrophobia, CMR images unsuitable for quantification, 
type 1 DM, severely uncontrolled DM, defined as glycated hemoglobin 
> 12%, and uncontrolled blood pressure at rest (defined as systolic blood 
pressure > 180 mm Hg and/or diastolic blood pressure > 100 mm Hg). 
Subjects with contraindications to MRI were not enrolled.
The study was approved by our institutional ethics committee. Each 
subject gave written informed consent.
Every eligible subject (controls and diabetic patients) underwent carotid 
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ultrasound study and cardiac MRI. Computed tomography for coronary 
artery calcium scoring was performed only in subjects with type 2 diabetes 
mellitus.
Carotid Ultrasound study
Scanning of the extra-cranial common carotid artery, the carotid bulb, and 
the internal carotid artery in the neck was performed by an experienced 
observer bilaterally in the longitudinal and transversal planes, using a GE 
Healthcare logic 9 with a 9 linear (8 MHz) probe. Carotid intima-media 
thickness (CIMT) was measured in the common carotid artery as the 
distance between 2 parallel echogenic lines corresponding to the blood-
intima and media-adventitia interface on the posterior wall of the artery. 
Determinations of carotid intima-media thickness were performed at 
the site of the thickest point and values below 0.8 mm were considered 
as normal. Localized elevated lesions with maximum thickness of more 
than 1 mm, having a point of inflection on the surface of the intima-
media complex, were defined as “plaques”. Stenosis was defined as > 50% 
occlusion. 
Coronary artery calcium score, data acquisition and analysis 
Coronary artery calcium (CAC) scoring was performed only in the DM2 
group, using a 64-slice CT scanner (LightSpeed VCT XT, GE Healthcare, 
Milwaukee, USA). For this purpose, a non-enhanced low-dose ECG-gated 
scan was performed with prospective triggering at 75% of the R–R interval. 
All examinations included the entire coronary tree and were performed 
with the patient breath-holding in inspiration. Scan parameters were as 
follows: field of view of 25 cm, slice thickness of 2.5 mm, gantry rotation 
time 0.35 s, tube current 100–400 mA, and tube voltage 120 kV. 
CAC score was determined by an experienced observer using dedicated 
software (SmartScore, version 4.0, GE Healthcare, Milwaukee, USA). Total 
CAC score was calculated for each patient using the Agatston method.
Cardiovascular magnetic resonance protocol
CMR imaging was performed by using a 3.0-T unit (Magnetom Trio; 
Siemens, Erlangen, Germany). Cardiac cine images were acquired 
by using steady-state free-precession sequences with retrospective 
electrocardiographic gating. Participants were imaged in the supine 
position and performed a breath-hold at end expiration for each image 
acquisition to eliminate respiratory motion artifacts. After scout images 
were obtained, cine imaging was performed in four-chamber, three-
chamber, and two-chamber long- and short-axis views with the use of 
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the following parameters: 8-mm-thick sections with a 2-mm gap between 
sections, repetition time 59.04 ms, echo time1.45, number of segments 
18; 50°flip angle, 256×156-mm matrix, 2.1 ×1.6-mm pixel size, acquired 
temporal resolution 25-40 ms; and number of reconstructed cardiac 
phases, 25.
A breath-held, retrospectively vector-ECG gated, two-dimensional flow-
sensitive phase-contrast gradient-echo sequence was used for velocity 
encoded (VENC) MRI flow measurements perpendicular to the orifice 
of the mitral valve. VENC-MRI slices were positioned in early diastole at 
the tip of the mitral valve leaflets. Typical imaging parameters of VENC-
MRI were as follows: slice thickness 6 mm, repetition time 35.6,ms, echo 
time 2.33 ms, number of segments 3, acquired temporal resolution 24-
56ms, 20° flip angle, 25 calculated phases and pixel spacing 4.5×3.1 mm. 
Encoding velocity was set to 130 cm/s.
MR image analysis
Quantitative image data analysis was performed by using dedicated 
software (Segment, version 1.8, Medviso, Lund, Sweden). All functional 
evaluations were performed within 25 minutes per patient.
Tracing of endocardial and epicardial contours
All measurements were undertaken semi-automatically. End-diastolic and 
end-systolic frames were identified according to the ventricular blood pool 
area. In all LV short-axis slices across all temporal phases (200-250 images) 
endocardial and epicardial contours were semi-automatically drawn and 
manually corrected. This segmentation took on the order of 3–5 minutes. 
At the base of the left ventricle, the aortic outflow tract below the valve 
was included in volume measurements. The free papillary muscles were 
included for LV mass assessment, and excluded for left ventricular volume 
assessment. In the basal region of the heart where the left atrium was seen, 
only the portion of the slice that could be identified as the left ventricle 
was included for measurement.
This analysis provided the time-varying course of the LV volume during 
the cardiac cycle. The peak filling rate (PFR) is the steepest tangent to the 
first part of the filling curve. Segment software automatically determines 
this parameter.
Analysis of the transmitral flow
In the flow sensitive sequence, a round region of interest was placed at 
the center of the mitral valve orifice on a diastolic image and propagated 
to other phases to obtain the transmitral curve. From the analysis of the 
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transmitral flow curve, the following measurements were performed: 
early phase of ventricular filling (E) and atrial phase of ventricular filling 
(A) mean peak velocities (in centimeters per second) and peak E velocity–
to–peak A velocity (E/A) ratio.
Left atrial measurements
Left atrial volume measurements were performed in the four- and 
two-chamber orientations by the biplane area-length methods. In the 
analysis we excluded the atrial appendage and the pulmonary veins. The 
parameters of LA size and function included in our analyses were:
- LA minimum volume (LAmin): LA end-diastolic volume at the first frame 
after mitral valve closure. 
- LA maximum volume (LAmax): LA end-systolic volume right before mitral 
valve opening.
LA reservoir function 
- Total LA stroke volume (LASV) = LAmax − LAmin. 
- Total LA ejection fraction (LAEF) = total LASV/LAmax
LA contractile function
- Active LASV: directly obtained by VENC-MRI from transmitral flow curves, 
using a MATLAB script.
- LA volume pre-atrial contraction (LApreA) = LAmin + Active LASV
- Active LAEF = active LASV/LApreA 
LA conduit function
- Passive LASV = LA max - LApreA
- Passive LAEF = passive LASV/LAmax
Statistical analysis
All data were systematically and prospectively entered in a database. 
The extensive database formed the basis for the studies presented in this 
thesis. 
At the time of writing this thesis, patients are still being enrolled.
All continuous variables were tested for normal distribution. All 
normally distributed data are expressed as means ± standard deviations. 
Categorical variables are expressed as counts and percentages. Between-
group differences of the average were compared using the unpaired 
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Student’s t-test for parametric data and the Mann-Whitney U test for non-
parametric data. Between-group differences in numbers and percentages 
were compared using the Chi-squared test (Fisher’s exact test).
Pearson’s correlation test was used for sets of normal variables. Independent 
associations were studied by using a linear regression with multivariable 
adjustments for potentially confounding factors.
P-values of less than 0.05 were considered statistically significant. All 
computations were performed using software (SPSS, version 20.0; SPSS, 
Chicago, IL, USA).
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1. Abstract
Objectives
Asymptomatic left ventricular (LV) diastolic dysfunction is increasingly 
recognised as an important diagnosis. Our goal was to study the prevalence 
and gender differences in subclinical LV diastolic dysfunction, using 
cardiovascular magnetic resonance imaging (CMR) at 3 T.
Methods
We prospectively studied 48 volunteers (19 male and 29 female, mean age 
49±7 years) with no evidence of cardiovascular disease. We used CMR to 
measure left atrium (LA) and LV volumes, LV peak filling rate and transmitral 
flow.
Results
The overall prevalence of LV diastolic dysfunction in our cohort varied 
between 20% (based on evaluation of LV filing profiles) and 24% (based on the 
evaluation of the transmitral flow). The prevalence of diastolic dysfunction was 
higher in men than in women, independently of the criteria used (P between 
0.004 and 0.022).
Indexed LV end-diastolic volume, indexed LV stroke volume, indexed LV 
mass, indexed LA minimum volume and indexed LA maximum volume were 
significantly greater in men than in women (P<0.05).  All the subjects had LV 
ejection fractions within the normal range.
Conclusions
It is clinically feasible to study diastolic flow and LV filling with CMR.
CMR detected diastolic dysfunction in asymptomatic men and women.
Key Points
CMR imaging offers new possibilities in assessing left ventricular diastolic 
function.
The prevalence of diastolic dysfunction is higher in men than in women.
The prevalence of some diastolic dysfunction in a normal population is 24%. 
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2. Introduction
Diastolic heart failure (HF) is a progressive disorder characterized by 
impaired left ventricular (LV) relaxation, increased LV stiffness, increased 
interstitial deposition of collagen, and modified extracellular matrix 
proteins. Diastolic HF, also referred to as HF with normal ejection fraction, 
currently accounts for 40-50% of all HF cases and has a prognosis which 
is as ominous as that of systolic HF. Clinical consensus places special 
emphasis on the detection of subclinical LV systolic and diastolic 
dysfunction and the timely identification of risk factors for heart failure 
(1). Fundamental structural and functional properties of the left ventricle 
(LV) and of the left atrium (LA) including parameters of diastolic function 
are often assessed in the clinical setting using two-dimensional and tissue 
Doppler echocardiography. Over the last decade, cardiovascular magnetic 
resonance (CMR) imaging has been widely accepted as the “gold standard” 
for the assessment of cardiac structure and function because of its high 
spatial and temporal resolution, excellent image quality and lack of 
geometric assumptions (2). CMR offers a variety of alternative approaches 
for evaluating diastolic function (3).
So far, few MRI-based studies of left ventricular diastolic dysfunction have 
been carried out. Several studies have defined CMR normal ranges of LV 
volumes and systolic function (4-11) but none has assessed the prevalence 
of left ventricular diastolic dysfunction in healthy adult individuals. 
The aim of the study was, therefore, to evaluate the prevalence of diastolic 
dysfunction in a normal population and to determine gender-specific 
differences for left heart volumes and function, using CMR at 3 T. 
3. Materials and methods
Study population
Forty-eight healthy volunteers (19 male and 29 female, mean age 49±7 
years, mean height 165±8 cm, mean weight 68±11 kg, with normal left 
ventricular ejection fraction, no history of cardiac disease, hypertension 
or other cardiac risk factors and a normal baseline electrocardiogram 
(ECG) were recruited. Exclusion criteria included a personal history of any 
condition that might be associated with systemic inflammation (such 
as systemic inflammatory arthritis or chronic chest disease) and signs of 
valvular disease in cine CMR imaging. Volunteers with contraindications 
to CMR were not enrolled.  The study was approved by our institutional 
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ethics committee. Each subject gave written informed consent.
Cardiovascular magnetic resonance protocol
CMR imaging was performed by using a 3.0-T unit (Magnetom Trio; Siemens, 
Erlangen, Germany). Cardiac cine images were acquired by using steady-
state free-precession sequences with retrospective electrocardiographic 
gating. Participants were imaged in the supine position and performed 
a breath-hold at end expiration for each image acquisition to eliminate 
respiratory motion artefacts. After scout images were obtained, cine 
imaging was performed in four-chamber, three-chamber, and two-
chamber long- and short-axis views with the use of the following 
parameters: 8-mm-thick sections with a 2-mm gap between sections, 
repetition time 59.04 ms, echo time1.45, number of segments 18; 50°flip 
angle, 256×156-mm matrix, 2.1 ×1.6-mm pixel size, acquired temporal 
resolution 25-40 ms; and number of reconstructed cardiac phases, 25.
A breath-held, retrospectively vector-ECG gated, two-dimensional flow-
sensitive phase-contrast gradient-echo sequence was used for velocity-
encoded (VENC) MRI flow measurements perpendicular to the orifice of 
the mitral valve. VENC-MRI slices were positioned in early diastole at the tip 
of the mitral valve leaflets. Typical imaging parameters of VENC-MRI were 
as follows: slice thickness 6 mm, repetition time 35.6 ms, echo time 2.33 
ms, number of segments 3, acquired temporal resolution 24-56 ms, 20° 
flip angle, 25 calculated phases and pixel spacing 4.5×3.1 mm. Encoding 
velocity was set to 130 cm/s (12).
MR image analysis
Quantitative image data analysis was performed by using dedicated 
software (Segment, Medviso, Lund, Sweden) (13). All functional evaluation 
was performed within 25 min per patient.
Tracing of endocardial and epicardial contours
All measurements were undertaken semi-automatically. End-diastolic and 
end-systolic frames were identified according to the ventricular blood pool 
area. In all LV short-axis slices across all temporal phases (200-250 images) 
endocardial and epicardial contours were semi-automatically drawn and 
manually corrected (Fig. 1). 
82     |     Chapter IV
Fig. 1 Semi-automatic left ventricular (LV) segmentation performed on short-axis 
views obtained with cine sequences for volumetric assessment of global LV filling.
This segmentation took on the order of 3–5 min. At the base of the LV, the 
aortic outflow tract below the valve was included in volume measurements. 
The free papillary muscles were included for LV mass assessment, and 
excluded for left ventricular volume assessment. In the basal region of the 
heart where the LA was seen, only the portion of the slice that could be 
identified as the LV was included for measurement.
This analysis provided the time-varying course of the LV volume during 
the cardiac cycle. The peak filling rate (PFR) is the steepest tangent to 
the first part of the filling curve (Fig. 2). Segment software automatically 
determines this parameter.
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Fig. 2 Left ventricular (LV) filling volume versus time curve and its first derivative, the 
peak filling rate curve. The LV volume versus time curve and its first derivative (LV dV/
dt) are obtained after the endocardial delineation of all LV short-axis slices across all 
temporal phases. The peak filling rate is the steepest tangent to the first part of the 
filling curve and represents the most rapid ventricular filling.
LA volume measurements were performed in the four- and two-chamber 
orientations by the biplane area-length methods. The following parameters 
of LA size and function were included in our analyses:
- LA minimum volume (LAVmin): LA end-diastolic volume at the first frame 
after mitral valve closure
- LA maximum volume (LAVmax): LA end-systolic volume right before 
mitral valve opening
- LA total emptying volume (LAEV): LAVmax − LAVmin
- LA total emptying fraction (LAEF): 100 × (LAVmax −LAVmin)/LAVmax
- LA conduit volume (LACV): LV stroke volume − LAEV
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Analysis of the transmitral flow (TMF)
In the flow sensitive sequence, a round region of interest with a minimum 
of 1 cm2 was placed at the centre of the mitral valve orifice (Fig. 3) and 
propagated to other phases to obtain the TMF curve (Fig. 4). 
Fig. 3 Measurement of transmitral flow. Phase-encoded MRI obtained with a phase-
contrast sequence shows a region of interest placed at the centre of the mitral orifice. 
The transmitral flow curve is obtained from this region of interest.
Fig. 4 Cardiac MR findings of the transmitral flow. The transmitral flow curve is 
composed of two peaks. The first one is the E wave and second one is the A wave. The 
E wave corresponds to rapid LV filling at early diastole; the A wave corresponds to late 
LV filling during end-diastole, secondary to LA contraction.
From the analysis of the TMF curve, the following measurements were 
performed: E and A mean peak velocities (in centimetres per second), E/A 
ratio, and mitral deceleration time (MDT) (measured from the E peak to 
the baseline).
Graça B, Ferreira MJ, Donato P, Castelo-Branco M, and Caseiro-Alves F. 
Eur Radiol. 2014;24(1):52-9
Cardiac MRI assessment of diastolic dysfunction in a population without heart disease     |     85
Statistical analysis
All data were subjected to Shapiro-Wilk tests to establish normal 
distribution of the data. All normally distributed data are expressed as 
means ± standard deviations. Differences between means of women and 
men were assessed using Student’s t-test for independent samples. The 
chi-squared test (Fischer’s exact test) was used to determine a relation 
between the parameters diastolic dysfunction and gender. P values of less 
than 0.05 were considered statistically significant. All computations were 
performed using software (SPSS, version 20.0; SPSS, Chicago, IL, USA).
4. Results
This study included 48 (19 male and 29 female) subjects. Table 1 displays 
the baseline characteristics for the current study population.
Table 1 Baseline characteristics of the study population according to gender
Female 
(n=29)
Male 
(n=19)
P
Age (years) 47±6 52±8 0.018
Height (cm) 160.4±5 172.9±5.3 < 0.001
Weight (kg) 62.9±8.7 76.6±9.8 < 0.001
BSA (m2) 1.67±0.13 1.92±0.14 < 0.001
BMI (kg/m2) 24.4±3.2 25.6±2.4 0.175
BSA body surface area, BMI body mass index
Gender differences in left ventricular measures 
Table 2 lists the values obtained for LV mass, end diastolic volume (EDV), 
end systolic volume (ESV), stroke volume (SV) and ejection fraction (EF), 
according to gender.
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Table 2 Left ventricular (LV) measurements according to gender
Female (n=29) Male (n=19)  P
LV EDV (mL) 103.0±17.0 136.3±24.4 < 0.001
LV EDV / BSA (mL/m2) 61.9±10.8 71.0±10.9 0.007
LV ESV (ml) 35.9±11.7 46.4±12.5 0.006
LV ESV / BSA (mL/m2) 21.6±6.6 24.1±6.1 0.178
LV SV (ml) 67±10.4 90±16.4 < 0.001
LV SV / BSA (mL/m2) 40.4±7.1 47.0±7.9 0.005
LV EF (%) 66±5.6 66.6±5.7 0.693
LV mass (g) 107.8±14.7 134.7±18.6 < 0.001
LV mass / BSA (g/m2) 65.1±7.7 70.4±8.9 0.038
LV left ventricle, EDV end diastolic volume, BSA body surface area, ESV end systolic volume, SV stroke 
volume, EF ejection fraction 
Indexed LV end-diastolic and stroke volumes were significantly greater in 
men than in women (P=0.007 and P=0.005, respectively). The indexed LV 
myocardial masses at end diastole were significantly greater in males than 
in females (P=0.038).
All the subjects had LV EFs within the normal range (male, range 55–85%; 
female, range 56–85%) published for healthy individuals at MRI and no 
significant gender differences were noted in this parameter.
Gender differences in left auricular measures 
Table 3 lists the values obtained for LA volumes and reservoir function, 
according to gender.
Table 3 Left atrium (LA) measurements according to gender
 Female (n=29) Male (n=19) P
LAVmin (mL) 26.3±8.2 36.9±11.7 0.002
LAVmin/BSA (mL/m2) 15.7±4.8 19.2±6.2 0.046
LAVmax (ml) 62.7±16.4 84.0±21.1 0.001
LAVmax / BSA (mL/m2) 37.5±9.3 43.8±10.1 0.032
LAEV (ml) 36.4±11.6 47.2±14.4 0.010
LAEV / BSA (mL/m2) 21.8±6.6 24.5±6.8 0.176
LACV (ml) 30.9±13.2 42.2±16.0 0.016
LACV / BSA (mL/m2) 18.7±8.4 21.8±8.8 0.235
LAEF (%) 57.4±9.3 56.4±8.9 0.698
LAVmin Left atrium minimum volume, LAVmax LA maximum volume, LAEV LA total emptying volume, 
LACV LA conduit volume, LAEF LA total emptying fraction, BSA body surface area
Indexed LA minimum and maximum volumes were significantly greater in 
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men than in women (P=0.046; P=0.032, respectively). Although absolute 
values of LA total emptying and conduit volumes were significantly greater 
in men than in women (P=0.01; P=0.016, respectively), the respective 
indexed volumes were comparable (P=0.176; P=0.235). Values of LAEF 
were similar in both genders (P=0.698)   
Gender differences in left ventricular diastolic measures 
Table 4 lists the values obtained for LV parameters of diastolic function, 
according to gender. Two subjects were excluded from the study because 
of intense motion artefacts during the flow-sensitive acquisition.
Table 4 LV diastolic function measurements according to gender
Female (n=27) Male (n=19) P
LV PFR (mL/s) 360.9±84.0 429.6±139.7 0.043
LV PFR/EDV (mL/s) 3.58±0.8 3.22±1.2 0.246
LV PFR/SV (mL/s) 5.51±1.4 4.9±1.8 0.208
Mitral peak E velocity (cm/s) 51.8±8.3 47.7±10.2 0.164
Mitral peak A velocity (cm/s) 39.5±8.2 41.6±9.7 0.446
Mitral E/A ratio 1.35±0.4 1.19±0.3 0.147
Mitral deceleration time (ms) 164±31 181±48 0.176
LV left ventricle, PFR peak filling rate, EDV end diastolic volume, SV stroke volume
Absolute values of PFR was significantly greater in men than in women 
(P=0.043).
The indexed (to EDV and SV) values of peak filling rate in women and men 
subjects were comparable (P=0.246; P=0.208). The analysis of transmitral 
parameters showed no gender differences. Mitral peak E (P=0.164) and 
peak A (P=0.446) velocities were comparable in women and men. Values 
of the E/A ratio (P=0.147) and MDT (P=0.176) were also similar in both 
genders.
Prevalence of diastolic dysfunction
A PFR normalised to EDV of less than 2.5 EDV/s was considered abnormal 
(14-16). This analysis was repeated using a PFR normalised to the stroke 
volume (SV), with a PFR less than 4SV/s considered abnormal (17-18).
The criteria for diastolic dysfunction from the analysis of the TMF curve 
were established according to published data (12). Normal diastolic 
function was defined as an E/A between 1 and 2 and MDT between 150 
and 220 ms. In grade I dysfunction, E/A decreases below 1. In grade II, E/A 
moves back into the normal range of 1–2, MDT is also normal, but there is 
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LA dilatation (LAVmax / BSA (mL/m2) greater than 52 in women or greater 
than 53 in men). In grades III and IV, E/A increase to a value above 2 and 
MDT drops below 150 ms. One male patient of 70 years of age with a mitral 
E/A ratio of 0.74 and MDT of 162 ms was established as a normal subject. 
We maintained the diagnosis of diastolic dysfunction in a 63-year-old man 
with a mitral E/A ratio of 0.68 and MDT of 234 ms (19).
Table 5 lists the prevalence of LV diastolic dysfunction, according to gender 
and the criteria used.
 Table 5 Prevalence of LV diastolic dysfunction diagnoses according to gender
Criteria All
(n=46)
Female 
(n=27)
Male 
(n=19)
P
LV PFR/EDV (mL/s) < 2.5 9 (20 %) 2 (7 %) 7 (37 %) 0.022
LV PFR/SV (mL/s) < 4 9 (20 %) 2 (7 %) 7 (37 %) 0.022
Transmitral flow analysis 11 (24 %) 2 (7 %) 9 (47 %) 0.004
Mitral E/A ratio < 1 6 (13 %) 2 (7 %) 4 (21 %) 0.213
Mitral E/A ratio 1–2 and LAVmax 
/ BSA (mL/m2) > 52 in women or 
> 53 in men
5 (11 %) 0 (0 %) 5 (26 %) 0.008
LV left ventricle, PFR peak filling rate, EDV end diastolic volume, SV stroke volume, LAVmax left atrium 
maximum volume, BSA body surface area
When patients were classified as having normal and abnormal PFR on the 
basis of a threshold of 2.5 EDV/s, 9 (7 male and 2 female, P= 0.022) patients 
were found to have diastolic dysfunction. When the PFR was normalised 
to the SV and analyses were repeated using a PFR less than 4 SV/s as 
abnormal, the number of patients with diastolic dysfunction was also 9 (7 
male and 2 female, P= 0.022).
When the patients were classified as having diastolic dysfunction on 
the basis of TMF analysis and LA size, 11 (9 male and 2 female, P=0.004) 
patients were found to have grade I or grade II diastolic dysfunction. None 
of the subjects showed grade III diastolic dysfunction.
5. Discussion
Gender differences in left ventricular measures 
Gender-specific differences include all absolute functional and 
morphological values except for EF. Normalisation to BSA eliminated 
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differences in LV ESV. Several studies (5–11) have described overall values 
of EDV, ESV, SV, LV mass and EF, which are consistent with findings from 
other imaging techniques and are broadly consistent with the findings 
in this study. Regarding the use of 3 T equipment in our study, published 
data suggest that field strength does not have an influence on the 
quantification of cardiac volume or mass, and normal values for cardiac 
volumes and mass established at 1.5 T can be applied to images obtained 
at 3 T (20).
Gender differences in left atrial measures 
We observed that nearly all non-indexed LA volumes were significantly 
higher in men, except for the left atrial emptying fraction. While these 
differences disappeared in most normalised parameters, indexed LA 
minimum and maximum volumes remained higher in men. Hudsmith et 
al (6, 21) also reported higher absolute LA volumes in male patients with 
similar ejection fraction in patients of both genders. Regarding indexed 
LA volumes, our findings are broadly consistent with Maceira et al (4). 
The effect of age may explain the greater indexed LA maximum volumes 
observed in men. Gender differences in the indexed LA minimum volume 
may be due to the decreased ejection force of the atrial pump in men, 
in a Frank Starling-like mechanism (22). This could be further clarified by 
the analysis of LA active pumping volume and index, which we did not 
perform.
Gender differences in left ventricular diastolic measures 
Although absolute LV PFR values were significantly higher in men, the 
parameter indexed for EDV or SV was higher in women, but not significantly 
so.
Regarding the evaluation of the TMF, there were no gender differences. 
One of the largest cohort studies with mitral flow-derived indices 
published (23) also showed no gender difference in E/A ratio. Previous 
studies have demonstrated a good correlation between cardiac MRI and 
echocardiography Doppler for measurement of flow velocities (2, 24, 25). 
Nevertheless there are no significant data from cardiac MR studies in a 
general population. 
Prevalence of diastolic dysfunction
The proportion of patients with an abnormal diastolic function is variable 
in the population depending on the criteria used. The prevalence reported 
here (between 20% and 24%) is consistent with larger population studies 
(26-29). 
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The gold standard for assessing diastolic function remains the pressure-
volume relationship, but this requires an invasive approach. Conventionally, 
echocardiographic Doppler measurements of MV flow conditions are used 
to assess diastolic function. CMR is a valid alternative for those patients 
who do not have adequate echocardiographic image quality to reliably 
obtain these parameters (1).
Flow analysis with CMR allows the quantitative assessment of blood 
velocity, with the advantage that the tomographic plane of interest can be 
positioned optimally in a larger area than Doppler echocardiography. CMR 
provides velocities (metres per second) as well as volume flow (millilitres 
per second) (30) and is less operator and angle dependent (31). Lower 
transmitral E/A ratios reflect impaired myocardial relaxation, characterised 
by decreased early, but enhanced atrial filling of the LV. In subjects with 
transmitral E/A ratio between 1 and 2, to establish a diagnosis of grade 
II diastolic dysfunction, we used the criterion of increased LA maximum 
volume, as it often reflects the cumulative effects of filling pressures over 
time (1).
Left ventricular filling profiles have been used to assess diastolic function 
by other imaging investigations, such as radionuclide cineangiography 
and SPECT. Similar applications for CMR imaging have been impractical 
because manual planimetry of all LV images across all temporal phases 
would typically require tracing of more than 200 images per patient. With 
the improvements in post-processing tools it is now possible to semi-
automatically segment all phases and quickly provide the time-varying 
course of the LV volume during the cardiac cycle. The ventricular relaxation 
abnormalities can be diagnosed by a low PFR. This evaluation is based on 
conventional short-axis sequences, without the necessity to perform a 
dedicated acquisition. The cut-off used to define the abnormal PFR has 
been applied to nuclear medicine tests. The use of indexed values of PFR 
to EDV and SV minimises the dependency of PFR from EDV and heart rate. 
We demonstrated that the left ventricular PFR can be easily obtained as 
an addition to the assessment of LV systolic function with semi-automatic 
contour detection and it may become a valuable asset to the evaluation 
of LV diastolic function.
Gender differences in the prevalence of diastolic dysfunction
The effects of age and hormonal protection may explain the lower 
prevalence of diastolic dysfunction in women.
The incidence of diastolic dysfunction increases with age (26) and seems 
to be affected by the postmenopausal state. Hormone replacement 
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therapy may improve LV diastolic function as one of the mechanisms of its 
cardioprotective effects (32). 
Although we did not find any gender differences regarding body mass 
index (BMI), the increased weight and body surface area (BSA) of men 
compared with women may also be related to the higher prevalence of 
diastolic dysfunction in this gender.
We recognise the limitations of our study. The sample size of the study is 
modest and our findings need to be validated in a larger population. 
The normal controls did not undergo a stress test to rule out latent 
ischaemia. However, none of the controls had significant cardiac risk 
factors.
We considered that the analysis of cine and TMF images was sufficient to 
exclude left-sided valvular disease. Regarding the exclusion of infiltrative 
myocardial disease, we did not study myocardial delayed enhancement 
nor did we perform endomyocardial biopsy. Nevertheless, none of our 
subjects had increased LV myocardial end-diastolic thickness, pericardial 
thickening, pericardial effusion or pleural effusion.
Cardiac catheterisation was not performed to evaluate LV diastolic 
function.
The use of another imaging technique such as echocardiography Doppler 
to study TMF and to assess LA size and function was considered beyond 
the scope of the present study. 
Although good correlation between echo Doppler studies and MRI has 
been reported, the cut-off values used in echocardiography cannot simply 
be translated to these MRI-assessed indices based on the time–flow rate 
curves. 
Normalising early mitral velocity (E) for the influence of myocardial 
relaxation by combining E with early diastolic mitral septal tissue velocity 
(Ea) may be performed by MR tissue phase contrast imaging, and this is 
an important criterion that has been established (19). On the other hand 
there are still conflicting data regarding the relation between E/Ea ratio 
and LV filling pressure (33, 34).
It is demonstrated that an LA volume index greater than 34 mL/m2 is 
an independent predictor of death, heart failure, atrial fibrillation, and 
ischaemic stroke. However, we recognise that dilated left atria may be seen 
in patients with bradycardia and four-chamber enlargement, anaemia and 
other high-output states, atrial flutter or fibrillation, and significant mitral 
valve disease, in the absence of diastolic dysfunction. We used a cut-off 
that was clearly higher (LAVmax / BSA (mL/m2) greater than 52 in women 
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or greater than 53 in men subjects) and we think that this eliminated most 
if not all of these potential confounding conditions.
This study highlights certain key points for the routine use of CMR to study 
diastolic function. Firstly, it is clinically feasible to study left heart volumes 
and function, including diastolic flow and LV filling data in a single CMR 
examination. Secondly, the prevalence of diastolic dysfunction in a normal 
adult population has clinical importance in view of the high risk in patients 
with impaired LV diastolic function.
In conclusion, our observations provide promising initial results for the 
routine use of CMR to study the prevalence and gender differences in 
subclinical LV diastolic dysfunction.
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1. Abstract
Objectives
The left atrium (LA) modulates left ventricular filling through reservoir, 
conduit and booster pump functions. Only limited data exist on LA 
involvement in type 2 diabetes mellitus (DM2).
This study sought to assess LA function in asymptomatic DM2 with 
cardiac MRI. We hypothesized that cardiac MRI can detect LA dysfunction 
in asymptomatic DM2.
Methods
Forty-five patients with asymptomatic DM2 and 24 normoglycemic 
controls were studied. MRI cine scan was performed to measure LA 
maximal and minimal volumes. A flow-sensitive phase-contrast gradient-
echo sequence was used for flow measurements perpendicular to the 
orifice of the mitral valve, to quantify active LA stroke volume. LA total, 
passive and active emptying volumes, and fractions were calculated.
Results
LA reservoir function, namely LA total ejection fraction, was significantly 
greater in controls compared to patients with DM2 (62.2±5.2 vs 57.0±7.6%, 
P=0.004). LA passive ejection fraction was also greater in the controls 
(26.2±9.5 vs 16.1±11.0%, P<0.001). Regarding parameters of LA booster 
pump function, LA active ejection fraction were not significantly different 
between groups. DM2 demonstrated to be an independent determinant 
of LA function. 
Conclusions
Cardiac MRI enables the detection of LA dysfunction in asymptomatic 
DM2, characterized by a reduction in LA reservoir and conduit functions.
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2. Introduction
Patients with type 2 diabetes (DM2) have an increased risk of developing 
cardiovascular disease, resulting in significant cardiac morbidity and 
mortality (1). In DM2 morphological changes suggestive of heart disease 
may appear before symptoms arise and the prevalence of subclinical left 
ventricular (LV) dysfunction is increased among these patients (2). 
Several mechanisms may underlie LV dysfunction in DM2, including 
atherosclerosis, microinfarctions, mitochondrial dysfunction, lipotoxicity 
and accumulation of advanced glycation end products, leading to myocyte 
hypertrophy, perivascular fibrosis and increased quantities of matrix 
collagen (3). All suggested mechanisms conducting to LV dysfunction in 
DM2 include systemic phenomena that can also impact the function of 
the left atrium (LA).
Left atrial function has been conventionally divided into three phases 
across the different phases of the cardiac cycle. First, during ventricular 
systole and isovolumetric relaxation, the LA acts as a reservoir and 
stores pulmonary venous return. Then, during ventricular diastole, LA 
emptying consists of two distinct components in subjects with sinus 
rhythm: the early component is related to passive blood flow from the 
LA, the pulmonary veins and the LA appendage into the LV; and the late 
component is related to active LA contraction and is referred to as the 
LA booster function for LV filling (4). Through these varying mechanical 
functions, the LA modulates LV filling and plays a key role in maintaining 
an optimal cardiac performance.
LA volume and function are robust markers of cardiovascular risk 
and adverse cardiac outcome across a broad range of cardiovascular 
pathologies (5-7). A recent prospective observational follow-up study of 
DM2 patients without overt cardiovascular disease demonstrated that a 
dilated LA was a predictor of death and major cardiovascular events (8). 
Regarding LA function, its prognostic importance in diabetes has not 
been evaluated. 
Fundamental structural and functional properties of the left atrium are often 
assessed in the clinical setting using two-dimensional echocardiography. 
Cardiac MRI offers several inherent advantages for the assessment of LA 
size and function due to its high spatial resolution, superior endocardial 
border definition, and capacity for unrestricted multiplanar imaging, 
independent of acoustic windows that may limit echocardiography (9). 
Basic measurements of LA size and function can be achieved with cardiac 
MRI by using the images routinely taken for LV function assessment. 
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There are limited published data on LA involvement in DM2 (10, 11), 
and as far as we are aware, there is no study about the role of MRI in the 
evaluation of LA function in DM2. Accordingly, the purpose of this study 
was to compare cardiac MRI–derived parameters of LA function between 
well-controlled uncomplicated DM2 and normoglycemic control subjects. 
Moreover, obesity and arterial hypertension are common in the clinical 
setting of DM2 and could also induce LA dysfunction.
So, we also aim to evaluate how DM2, arterial hypertension and body-
mass index influences LA function. 
We hypothesized that asymptomatic DM2 patients will have reduced LA 
function compared with normoglycemic control subjects.
3. Materials and methods
Study population
Forty-five patients with DM2 were prospectively recruited from the 
Endocrinology Department of our institution. Inclusion criteria included 
age between 45-75 years, no symptoms or history of overt heart disease, 
no signs or symptoms of cerebrovascular disease, no abnormal findings on 
routine clinical and physical examination and a normal rest ECG. Patients 
who had LVEF <55%, regional LV wall motion abnormalities and valvular 
heart disease, contraindications to MRI, glomerular filtration rate <30 mL/
min, glycated hemoglobin > 12%, systolic blood pressure > 160 mm Hg 
and/or diastolic blood pressure > 100 mm Hg, underlying cardiomyopathy, 
previous myocardial infarction, coronary revascularization, or previous 
cardiac surgery were excluded. Twenty-four healthy volunteers recruited 
from the local population served as control and had no history of heart 
disease, diabetes mellitus, or high cholesterol. They had a normal physical 
examination and ECG. All subjects gave informed consent to participate 
in the study, which was approved by our institutional ethics committee. 
Cardiac MRI protocol
All images were acquired with electrocardiographic gating, breath-
holding, and the patient in a supine position. Subjects were imaged on a 
3T MR system (Tim Trio, Siemens, Erlangen, Germany). The basic protocol 
consisted of cine steady-state free-precession imaging (TR, 3.4 ms; TE, 1.2 
ms; in-plane spatial resolution, 1.6 × 2.1 mm) for LV function and mass. 
Cine imaging was obtained in 8 to 12 matching short-axis (8 mm thick with 
2mm gap) and 3 standard long-axis planes (2-, 3- and 4-chamber views). 
For the calculation of LV mass and function, the endocardial and epicardial 
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borders of the LV myocardium were manually traced on successive short-
axis cine images at end-diastole and systole. 
A breath-held, retrospectively vector-ECG gated, two-dimensional flow-
sensitive phase-contrast gradient-echo sequence was used for velocity-
encoded (VENC) MRI flow measurements perpendicular to the orifice of 
the mitral valve. VENC-MRI slices were positioned in early diastole at the 
tip of the mitral valve leaflets. Typical imaging parameters of VENC-MRI 
were as follows: slice thickness 6 mm, repetition time 4.5 ms, echo time 
2.33 ms, number of segments 3, acquired temporal resolution 36 ms, 20° 
flip angle, 25 calculated phases and pixel spacing 4.5×3.1 mm. Encoding 
velocity was set to 130 cm/s (12, 13). Flow analysis was performed on the 
through-plane VENC-MRI phase-contrast and magnitude images acquired 
across the mitral valve. To determine total blood flow and volume, region 
of interest curves on the VENC-MRI phase-contrast images were drawn 
in the diastole at the mitral valve orifice and propagated to all phases to 
obtain the transmitral flow (TMF) curve (14) (Figure 1). From the analysis 
of the TMF curve, the following measurements were performed: E and A 
mean peak velocities (in centimetres per second), E/A ratio, and mitral 
deceleration time (MDT) (measured from the E peak to the baseline).
Fig. 1 Measurement of transmitral flow. Phase-encoded MRI image obtained with a 
phase-contrast sequence show a region of interest placed at the mitral orifice (arrow). 
The transmitral flow curve was obtained from this region of interest.
Left atrial measurements
Left atrial volume measurements were performed in the four- and 
two-chamber orientations by the biplane area-length methods. In the 
analysis we excluded the atrial appendage and the pulmonary veins. The 
parameters of LA size and function included in our analyses were:
- LA minimum volume (LAmin): LA end-diastolic volume at the first frame 
after mitral valve closure (Figure 2A and 2B). 
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- LA maximum volume (LAmax): LA end-systolic volume right before mitral 
valve opening (Figure 2C and 2D).
LA reservoir function 
- Total LA stroke volume (LASV) = LAmax − LAmin. 
- Total LA ejection fraction (LAEF) = total LASV/LAmax
LA contractile function
- Active LASV: directly obtained by VENC-MRI from transmitral flow curves 
(Figure 3), using a MATLAB script.
- LA volume pre-atrial contraction (LApreA) = LAmin + Active LASV
- Active LAEF = active LASV/LApreA 
LA conduit function
- Passive LASV = LA max - LApreA
- Passive LAEF = passive LASV/LAmax
Fig. 2 Measurement of left atrial minimal and maximal volumes. Cine-MRI slices were 
acquired in the two-chamber (upper row) and four chamber (lower row) long-axis 
orientation. Minimal (A and B) and maximal left atrial (C and D) volumes were calculated 
using the biplane area-length method. The atrial appendage and the pulmonary veins 
were excluded from the measurements.
MR image analysis
Quantitative image data analysis was performed by using dedicated 
software (Segment, Medviso, Lund, Sweden) (15). All functional evaluations 
were performed within 25 minutes per patient.
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Reproducibility
In 5 randomly selected studies from each group, 2 readers independently 
measured the LAmax, LAmin and active LASV. One observer remeasured 
the same 10 studies at a separate time to determine intraobserver 
agreement from the baseline studies. 
Fig. 3 MRI findings of transmitral flow. The transmitral flow curve is composed of two 
peaks. The first one is the E wave and second one is the A wave. The E wave corresponds 
to rapid LV filling at early diastole; the A wave corresponds to late LV filling during 
end-diastole, secondary to LA contraction. Active left atrial stroke volume was directly 
obtained from the analysis of the area under the A wave (filled in yellow).
Statistical analysis
All continuous variables were tested for normal distribution. All normally 
distributed data are expressed as means ± standard deviations. Categorical 
variables are expressed as counts and percentages. Differences between 
means of the DM2 group and controls were examined by the unpaired 
t-test. Between-group differences in numbers and percentages were 
compared using the Chi-squared test. 
Univariate and multiple analyses with a forward selection procedure were 
performed. The goal of these analyses was to determine which factors were 
responsible for the difference in LA phasic function (total LAEF and passive 
LAEF) between groups. We employed a 2-step strategy for the selection of 
variables. The first step was that a variable had to be significantly different 
between groups. If so, in univariate analysis there had to be an association 
between this variable and the dependent variable with P<0.1. The variables 
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fulfilling these criteria were then entered in a multivariable regression 
analysis, and those with P<0.05 were considered independently related 
to the dependent variable. Intraobserver and interobserver variability 
were assessed by using a Bland-Altman analysis. All computations were 
performed with software (SPSS, version 20.0; SPSS, Chicago, IL). 
4. Results
Demographic data and LV parameters of the DM2 group vs. controls are 
presented in Table 1. Body mass index was significantly increased in the DM2 
group (P<0.001). Our population of DM2 had a higher (53%) prevalence 
of systemic arterial hypertension (HT), although not significantly greater 
than the control group. 
All left ventricular volumes and masses were in the normal range, with no 
significantly difference between groups. 
Subjects with DM2 had significantly decreased diastolic functional 
parameters with greater mitral peak A velocity and lower mitral E/A ratio 
(P=0.010; P=0.002, respectively).
Table 1 Baseline characteristics of the study population and left ventricular 
measurements
DM2 
group (n=45)
Normoglycemic 
group (n=24)
P value
Age, y 58.9±6.9 55.8±6.8 0.081
Male, n (%) 24/45 (53) 14/24 (58) 0.801
Body surface area, m2 1.87±0.21 1.83±0.18 0.374
Body mass index, kg/m2 29.5±4.4 25.6±3.1 < 0.001
Hypertension, n (%)* 24/45 (53) 8/24 (33) 0.011
LV EDV / BSA, mL/m2 77.4±14.4 79.8±13.9 0.507
LV EF, % 61.6±7.2 64.5±5.6 0.119
LV mass / BSA, g/m2 64.6±13.1 62.4±13.4 0.529
Mitral peak E velocity, cm/s 42.3±11.9 46.4±11.6 0.168
Mitral peak A velocity, cm/s 50.3±10.7 43.9±8.9 0.010
Mitral E/A ratio 0.86±0.27 1.08±0.27 0.002
BP, blood pressure; LV, left ventricle; EDV, end-diastolic volume; BSA, body surface area; EF, ejection fraction.
*Blood pressure > 140/90 mmHg or treatment with anti-hypertensive medication.
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Intraobserver and interobserver variability of left atrial measurements
The intraobserver limits of agreement were −2.1 mL to 0.6 mL for LAmin, 
0.5 mL to 3.9 mL for LAmax and −2.1 mL to 1.2 mL for active LASV. The 
interobserver limits of agreement were 0.02 mL to 4.2 mL for LAmin, 
−3.0 mL to 2.6 mL for LAmax and −0.9 mL to 1.2 mL for active LASV. The 
corresponding intraclass correlation coefficient values were 0.99, 0.99, 
and 0.95 for the intraobserver analysis and 0.97, 0.98, and 0.98 for the 
interobserver analysis for LAmin, LAmax and active LASV, respectively.
Left atrial measures
Indexed LA minimum and maximum volumes were not significantly 
different between groups (Table 2).
Table 2 Left atrial measurements
DM2 group 
(n=45)
Normoglycemic 
group (n=24)
P value
LAmin / BSA, mL/m2 16.7±6.9 13.9±3.9 0.096
LAmax / BSA, mL/m2 37.7±11.0 36.0±7.6 0.488
Total LASV / BSA, mL/m2 21.0±5.8 22.1±4.4 0.431
Active LASV / BSA, mL/m2 13.8±3.6 13.2±3.9 0.522
Passive LASV / BSA, mL/m2 7.2±5.6 9.0±5.5 0.243
Total LAEF, % 56.9±8.2 62.2±9.3 0.034
Passive LAEF, % 27.6±18.2 45.3±15.5 < 0.001
Active LAEF, % 46.7±11.8 49.0±12.9 0.513
BSA, body surface area; LAmin, left atrial minimum volume; LAmax, left atrial maximum volume; LASV, 
left atrial stroke volume; LAEF, left atrial ejection fraction.
Parameters of LA reservoir function, namely total LAEF value, was 
significantly greater in the control group (P=0.034). 
Parameters of LA conduit function, namely LA passive ejection fraction 
value was also significantly greater in the control group (P<0.001).
Regarding parameters of LA booster pump function, including indexed 
LA active stroke volume and active LAEF values were not significantly 
different between groups. 
Factors that influence LA function
Table 3 outlines the univariate Pearson correlations for total and passive 
LAEF.
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Table 3 Univariate Pearson correlation coefficients analysis of total LAEF and passive 
LAEF  
Total LAEF Passive LAEF
Correlation 
Coefficient
P value
Correlation 
Coefficient
P value
Age 0.20 0.876 -0.30 0.017
Body mass index -0.22 0.083 -0.32 0.012
LV EDV / BSA, mL/m2 0.084 0.522 0.004 0.977
LV mass / BSA, g/m2 -0.172 0.184 -0.228 0.077
Mitral peak A velocity 0.15 0.190 -0.29 0.024
Mitral E/A ratio 0.07 0.583 0.48 <0.001
LAEF, left atrial ejection fraction.
There was no significant correlation between total LAEF and age, body-
mass index, LV ejection fraction, indexed LV mass, indexed end-diastolic 
LV volume, mitral peak A velocity and mitral E/A ratio. 
There was a significative, low to moderate negative correlation between 
passive LAEF and age, body mass index and mitral peak A velocity. There 
was a significative, moderate positive correlation between passive LAEF 
and mitral E/A ratio. There was no significant correlation between passive 
LAEF and LV ejection fraction, indexed end-diastolic LV volume and 
indexed LV mass.
To identify the independent determinants of total and passive LAEF 
univariate predictors with P<0.10 were all entered into a multiple linear 
regression model as covariates (Table 4). 
Table 4 Independent determinants of total LAEF and passive LAEF  
β P 
value
Total LAEF
Diabetes mellitus -0.15 0.017
Arterial hypertension -0.01 0.918
Body mass index 1.10 <0.001
Passive LAEF
Diabetes mellitus -0.18 0.182
Hypertension 0.04 0.67
Body mass index -0.03 0.927
Mitral peak A velocity 0.22 0.328
Mitral E/A ratio 0.89 <0.001
LAEF, left atrial ejection fraction.
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On multivariable analysis, total LAEF was independently influenced and 
reduced in DM2 and with increased BMI. Passive LAEF was related to E/A 
ratio. 
5. Discussion
In this study, MRI-derived parameters of LA function in patients with DM2 
were investigated. Differences in LA function were observed between 
DM2 patients and control subjects. LA phasic function is changed in 
asymptomatic DM2, with an associated decrease in reservoir (total LAEF) 
and conduit (passive LAEF) functions. Conversely, there was no change in 
LA booster function.
We have demonstrated that DM2 and body-mass index are independent 
determinants of LA reservoir function on multivariate analysis. Mitral E/A 
ratio is an independent determinant of LA passive function. 
Left atrial reservoir function
During LV systole and isovolumic relaxation, the LA functions as a reservoir, 
receiving blood from the pulmonary veins and storing energy in the form 
of pressure. This atrial function is mainly modulated by LV contraction, 
through the descent of the LV base during systole and by LA properties 
(i.e., relaxation and chamber stiffness) (16).
Our group of DM2 patients demonstrated lower total LA ejection 
fractions compared to normoglycemic controls. This could by explained 
by a decrease in LA compliance in the DM2 group (17) in the context of 
diabetic cardiomyopathy. An impairment of LA compliance in DM2 has 
been recently demonstrated by Kadappu et al (11), by showing that 
echocardiographic parameters of global and segmental strains of the LA 
were significantly reduced in subjects with DM2.
Left atrial conduit function
During early LV diastole, the pressure in the left atrium falls, and flow in 
the pulmonary veins increases. During this period, the left atrium acts 
as a passive conduit (conduit function of the left atrium) and blood is 
transferred into the LV through the LA via a small pressure gradient and 
flows passively from the pulmonary veins into the LV. Traditionally the 
LA passive stroke volume is not easily measured, because, while the 
mitral valve is open, some blood flows directly from the pulmonary veins 
and LA appendage (16).  In our study, we obtained the LA active atrial 
emptying volume directly by measurement of transmitral total flow across 
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all the area of the mitral valve, and added this volume to LA minimum 
volume to establish the LA volume before LA contraction. The LA passive 
stroke volume was obtained by subtracting this LA volume before LA 
contraction to LA maximum volume. This method is not confounded by 
passive diastolic blood flow from the pulmonary veins and LA appendage 
(18). Passive LA ejection fraction is the proportion of the LA passive stroke 
volume to LA maximum volume.
In our study DM2 patients demonstrated lower LA passive ejection fraction 
compared to normal controls. The explanation for this finding could reside 
in the LV. Left atrial passive stroke volume is effectively drawn into the 
left ventricle via LV suction, and it may be more appropriately viewed as 
a property of LV diastolic function rather than intrinsic LA function. This 
conduit function is modulated especially by LV diastolic properties (LV 
relaxation and early diastolic pressures) (19).
DM2-related changes in LV diastolic properties are well recognized with 
a decrease in early diastolic filling, directly influenced by abnormal LV 
relaxation, and an increased passive stiffness due to remodeling (20). In 
fact, the DM2 group of our study showed higher mitral peak A velocity 
and lower mitral E/A ratio compared to normal controls. Also, mitral E/A 
ratio was an independent determinant of LA conduit function. Higher 
mitral peak A velocity and lower mitral E/A ratio are markers of impaired 
LV relaxation (21), suggesting that there may be a link between LV diastolic 
properties and LA function. 
Left booster pump function
In the presence of a sinus rhythm, LV filling is completed by atrial contraction. 
The LA is a contractile chamber that actively empties immediately before 
the onset of LV systole and establishes final LV end-diastolic volume. LA 
booster pump function is mostly dependent on intrinsic atrial contractility 
and becomes increasingly important to the preservation of cardiovascular 
performance in the presence of reduced LV compliance (16). 
In our study, the parameters of LA booster pump function (active LA stroke 
volume and active LA ejection fraction) were similar in both groups.
Muranaka et al (10) showed also a reduction in atrial phasic function in 
diabetes mellitus, as measured by strain rate parameters. Their results point 
also to an impairment of LA reservoir and conduit functions in patients 
with DM2 (10). Asbun et al (17) demonstrated a relation between diabetic 
cardiomyopathy and a reduction in LA compliance. A recent study from 
van-Schinkel et al (22) also demonstrated an association of type 1 diabetes 
mellitus, aortic stiffness (determined by MRI-assessed pulse wave velocity) 
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and decrease in LA compliance (measured with echocardiographic 
speckle tracking strain analysis). Kadappu et al (11) evaluated LA function 
by strain and strain rate derived from 2D speckle tracking in patients with 
DM2. Patients with DM2 had altered phasic LA function with impaired LA 
reservoir, conduit and contractile functions (11).
The findings of our study contribute to the available knowledge, favoring 
the hypothesis that there is a relationship between DM2, obesity and left 
atrial dysfunction. 
The originality of our study is the use of cardiac MRI–derived parameters 
of LA function. 
While MRI represents the current gold standard for assessment of LA size 
and function (23), there are limited data available on this topic.
Traditionally, LA size and function has been studied with performing 
2-dimensional echocardiography. However, cyclic changes of LA volume 
may not be observed directly by 2-dimensional echocardiography because 
the shape of the LA changes during the heart cycle, and the pattern is 
influenced by the loading conditions (24). Therefore, 2-dimensional 
echocardiography presents only a snapshot view of the LA function. 
In contrast, MRI data acquisition is distributed to several cardiac cycles 
in segmented ECG-gated sequences. Thus, cardiac MRI has been proved 
to be an effective alternative for accurately assessing the LA volume and 
phasic function (25). 
There is growing evidence that LA size and function serves as an important 
diagnostic and prognostic factor in a variety of conditions, including 
DM2 (8). Therefore, comprehensive evaluation of LA function might be 
an important clinical factor to stratify the risk of preclinical cardiovascular 
disease and could be integrated into a routine cardiac MRI protocol for the 
evaluation of high-risk subjects, including patients with DM2.  
There are a few limitations to our study. This study was a case-control 
study with a relatively small number of subjects and our findings need to 
be validated in a larger population. 
Our findings are limited by an inability to eliminate causal relationships 
with important clinical factors, such as medications used, serum 
concentrations of glucose, and glycosilated haemoglobin, dyslipidaemia, 
retinopathy, microabuminuria and smoking status. 
The possibility of influence of myocardial ischemia or fibrosis on LV or 
LA function cannot be completely excluded. Although stress imaging 
is recommended for symptomatic type 2 diabetics, there is still no 
consensus on the best approach for screening asymptomatic diabetic 
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subjects without known coronary artery disease (26). In the absence of 
sufficient clinical indication, it was not deemed ethical to subject these 
asymptomatic subjects to gadolinium myocardial perfusion and delayed 
enhancement.
For the analysis of the LA volumes, a true volumetric approach such as the 
use of a contiguous short-axis stack, is preferred. However, the biplane 
area-length method is a validated good compromise between accuracy 
and speed, as it does not require extra image acquisition apart from that 
routinely taken for LV function assessment (27).
This study highlights certain key points for the routine use of cardiac MRI 
to study LA function in diabetic patients. 
First, evaluation of LA function is feasible with cardiac MRI. Second, body-
mass index and diabetes independently influence LA function. Third, 
cardiac MRI shows a decrease in LA reservoir and conduit functions in DM2 
and may allow the diagnosis of subclinical LA dysfunction in this high-risk 
population.
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1. Abstract
Objectives
The purpose of the current study was to compare cardiovascular magnetic 
resonance imaging (CMR)-derived parameters of left ventricular (LV) 
diastolic function between uncomplicated type 2 diabetes mellitus (DM2) 
and normoglycemic controls, and to evaluate whether these parameters 
of LV diastolic function are related to coronary atherosclerosis. 
Methods
We prospectively studied 41 subjects with DM2 and 21 normoglycemic 
controls (30 women and 32 men, mean age 57.2 ± 7.1 years) with no 
evidence of overt cardiovascular disease. We used CMR to measure LV 
volumes, LV peak filling rate (PFR) and transmitral flow; and CT to determine 
coronary artery calcium scores.
Results
Absolute values of the peak filling rate (PFR) were significantly lower in 
DM2 patients than in control subjects (mean ± SD, 293.2 ± 51.7 vs 375.7 
± 102.8 mL/s, respectively; P < 0.001). Mitral peak E velocities (mean ± SD, 
42.8 ± 10.7 vs 48.8 ± 10.4 cm/s; P = 0.040) and peak E velocity–to–peak A 
velocity ratios (0.88 ± 0.3 vs 1.1 ± 0.3; P = 0.002) were also lower in DM2 
patients compared with control subjects. DM2 patients with coronary 
artery calcification showed a lower PFR normalized to stroke volume 
(SV) (mean ± SD, 4.4 ± 1.0 vs 5.3 ± 1.4, respectively; P = 0.038) and lower 
mitral peak E velocities (40.1 ± 11.3 vs 48.0 ± 7.3 cm/s; P = 0.024) than 
DM2 patients without coronary calcification. PFR normalized to SV was 
independently associated with the presence of coronary artery calcifica- 
tion (β = –1.5, P = 0.005).
Conclusions
Type 2 diabetes mellitus decreases CMR-derived parameters of left 
ventricular diastolic function. Patients with type 2 diabetes mellitus and 
coronary atherosclerosis show a more impaired left ventricular diastolic 
function compared with patients without coronary atherosclerosis. 
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2. Introduction
Cardiovascular disease is the most frequent cause of death and disability 
in type 2 diabetes mellitus (DM2). 
Type 2 diabetes mellitus is responsible for diverse cardiovascular 
complications such as increased coronary atherosclerosis and left 
ventricular (LV) dysfunction. Left ventricular diastolic dysfunction is highly 
prevalent in patients with DM2 (1, 2), representing the earliest preclinical 
manifestation of LV dysfunction in this condition (3-6).
Over the last decade, cardiovascular magnetic resonance (CMR) imaging 
has been widely accepted as the “gold standard” for the assessment of 
cardiac structure and function because of its high spatial and temporal 
resolution, excellent image quality and lack of geometric assumptions 
(7). CMR offers a variety of alternative approaches for evaluating diastolic 
function (8, 9).
The presence of coronary calcium (CAC) is indicative of coronary 
atherosclerosis (10), which can be detected non-invasively by multidetector 
computed tomography (CT).
Coronary artery disease is commonly cited as a mechanism underlying 
diastolic dysfunction (11). Many of the same factors that contribute to 
atherosclerosis may also produce LV diastolic dysfunction by either direct 
mechanisms (e.g., hypertension and age-related vascular stiffening) or 
secondarily via coronary artery disease progression and resulting changes 
in myocardial compliance (11).
There are limited and controversial published data on the relationship 
of CAC to LV diastolic function. Edvardsen et al (12) demonstrated that 
coronary atherosclerosis is associated with depressed regional left 
ventricular systolic and diastolic wall strain, measured by MRI tagging. 
Colletti et al (13) demonstrated that CAC scores greater than 100 predicts 
an increased likelihood of clinically unsuspected left ventricular regional 
wall motion abnormalities, which are associated with lower LV ejection 
fractions and peak filling rates, as assessed with cardiac MRI. Eleid et al 
(14) study pointed to different conclusions. Their results in asymptomatic 
patients with normal LV ejection fraction and negative cardiac stress test 
showed that CAC does not correlate with LV diastolic function as defined 
by established Doppler echocardiographic criteria.
Although all of these studies included patients with DM2, none specifically 
studied this population. Accordingly, the purpose of the current study 
was to compare CMR-derived parameters of diastolic function between 
well-controlled uncomplicated DM2 and normoglycemic controls, and to 
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evaluate whether these CMR-derived parameters of LV diastolic function 
are related to coronary atherosclerosis
Cardiovascular magnetic resonance imaging was used to measure 
parameters of LV diastolic function, while the presence of coronary 
atherosclerosis was assessed by means of CAC scoring.
We hypothesize that in asymptomatic diabetic patients, diastolic function 
as measured by mitral flow velocities and peak filling rate (PFR) will be 
reduced with the presence of coronary atherosclerosis. We also hypothesize 
that asymptomatic diabetic patients will have reduced diastolic function 
compared to normoglycemic controls.
3. Materials and methods
Study population
We prospectively enrolled 41 subjects (21 women and 20 men) with 
DM2 enrolled based on referral to the outpatient clinical department 
of diabetology of our institution and 21 age and gender-matched 
normoglycemic controls (9 women and 12 men) recruited from the 
community.
Subjects were included if they met the following inclusion criteria: age 
between 45-75 years, no symptoms or history of overt heart disease 
(cardiomyopathy, coronary artery disease or valvular heart disease), no 
signs or symptoms of cerebrovascular disease, no abnormal findings on 
routine clinical and physical examination and a normal ECG. 
Exclusion criteria were: LV ejection fraction (LVEF) < 55%, regional LV wall 
motion abnormalities and valvular heart diseases assessed by CMR, severe 
renal failure, claustrophobia, CMR images unsuitable for quantification, 
type 1 DM, severely uncontrolled DM, defined as glycated hemoglobin 
> 12%, and uncontrolled blood pressure at rest (defined as systolic blood 
pressure > 180 mm Hg and/or diastolic blood pressure > 100 mm Hg). 
Subjects with contraindications to CMR were not enrolled.
The study was approved by our institutional ethics committee. Each 
subject gave written informed consent.
Coronary artery calcium score, data acquisition and analysis 
Coronary artery calcium (CAC) scoring was performed only in the DM2 
group, using a 64-slice CT scanner (LightSpeed VCT XT, GE Healthcare, 
Milwaukee, USA). For this purpose, a non-enhanced low-dose ECG-gated 
scan was performed with prospective triggering at 75% of the R–R interval. 
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All examinations included the entire coronary tree and were performed 
with the patient breath-holding in inspiration. Scan parameters were as 
follows: field of view of 25 cm, slice thickness of 2.5 mm, gantry rotation 
time 0.35 s, tube current 100–400 mA, and tube voltage 120 kV. 
CAC score was determined by an experienced observer using dedicated 
software (SmartScore, version 4.0, GE Healthcare, Milwaukee, USA). Total 
CAC score was calculated for each patient using the Agatston method 
(15). For the final analysis patients were categorized in two groups: Group 
1, CAC score > 0; Group 2, CAC score = 0.
Cardiovascular magnetic resonance protocol
CMR imaging was performed by using a 3.0-T unit (Magnetom Trio; 
Siemens, Erlangen, Germany). Cardiac cine images were acquired 
by using steady-state free-precession sequences with retrospective 
electrocardiographic gating (16). Participants were imaged in the supine 
position and performed a breath-hold at end expiration for each image 
acquisition to eliminate respiratory motion artifacts. After scout images 
were obtained, cine imaging was performed in four-chamber, three-
chamber, and two-chamber long- and short-axis views with the use of 
the following parameters: 8-mm-thick sections with a 2-mm gap between 
sections, repetition time 59.04 ms, echo time1.45, number of segments 
18; 50°flip angle, 256×156-mm matrix, 2.1 ×1.6-mm pixel size, acquired 
temporal resolution 25-40 ms; and number of reconstructed cardiac 
phases, 25.
A breath-held, retrospectively vector-ECG gated, two-dimensional flow-
sensitive phase-contrast gradient-echo sequence was used for velocity 
encoded (VENC) MRI flow measurements perpendicular to the orifice of 
the mitral valve. VENC-MRI slices were positioned in early diastole at the 
tip of the mitral valve leaflets. Typical imaging parameters of VENC-MRI 
were as follows: slice thickness 6 mm, repetition time 35.6,ms, echo time 
2.33 ms, number of segments 3, acquired temporal resolution 24-56ms, 20° 
flip angle, 25 calculated phases and pixel spacing 4.5×3.1 mm. Encoding 
velocity was set to 130 cm/s (9).
MR image analysis
Quantitative image data analysis was performed by using dedicated 
software (Segment, version 1.8, Medviso, Lund, Sweden) (17). All functional 
evaluations were performed within 25 minutes per patient.
Tracing of endocardial and epicardial contours
All measurements were undertaken semi-automatically. End-diastolic and 
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end-systolic frames were identified according to the ventricular blood pool 
area. In all LV short-axis slices across all temporal phases (200-250 images) 
endocardial and epicardial contours were semi-automatically drawn and 
manually corrected (Fig. 1). This segmentation took on the order of 3–5 
minutes. At the base of the left ventricle, the aortic outflow tract below the 
valve was included in volume measurements. The free papillary muscles 
were included for LV mass assessment, and excluded for left ventricular 
volume assessment. In the basal region of the heart where the left atrium 
was seen, only the portion of the slice that could be identified as the left 
ventricle was included for measurement.
This analysis provided the time-varying course of the LV volume during 
the cardiac cycle. The peak filling rate (PFR) is the steepest tangent to 
the first part of the filling curve (Fig. 2). Segment software automatically 
determines this parameter.
Analysis of the transmitral flow
In the flow sensitive sequence, a round region of interest with a minimum 
size of 1 cm2 was placed at the center of the mitral valve orifice on a 
diastolic image and propagated to other phases to obtain the transmitral 
curve (9). From the analysis of the transmitral flow curve, the following 
measurements were performed: early phase of ventricular filling (E) and 
atrial phase of ventricular filling (A) mean peak velocities (in centimeters 
per second) and peak E velocity–to–peak A velocity (E/A) ratio.
Statistical analysis
All continuous variables were tested for normal distribution. All normally 
distributed data are expressed as means ± standard deviations. Categorical 
variables are expressed as counts and percentages. Between-group 
differences of the average were compared using the unpaired Student’s 
t-test for parametric data and the Mann-Whitney U test for non-parametric 
data. Between-group differences in numbers and percentages were 
compared using the Chi-squared test (Fisher’s exact test).
The distribution of CAC score was skewed, and therefore, medians and 
ranges were reported. 
Logarithmic transformation of CAC scores— that is, log (total CAC score + 
1)—was used for parametric evaluation.
Pearson’s correlation test was used for sets of normal variables. Independent 
associations between coronary artery calcification and LV diastolic values 
were studied by using a linear regression with multivariable adjustments for 
potentially confounding factors (eg, age, gender, history of hypertension, 
body mass index, duration of diabetes, LV ejection fraction and LV mass 
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index).
P-values of less than 0.05 were considered statistically significant. All 
computations were performed using software (SPSS, version 20.0; SPSS, 
Chicago, IL, USA).
4. Results
Forty-one DM2 patients and 21 age- and sex-matched normoglycemic 
control sub- jects were studied. Demographic, clinical, and imaging data 
of the patients and control subjects are presented in Table 1. The mean 
age was 57.2 ± 7.1 years (age range, 45–72 years) and 32 (52%) patients 
were male. 
As expected, patients with DM2 had higher BMI (P<0.001) than controls. 
Our population of DM2 patients had a higher (P=0.001) prevalence of 
systemic arterial hypertension (HT), compared with controls.
Left ventricular function
Patients with DM2 had normal conventional parameters of systolic function 
including LVEF, and a normal LV mass index, compared with controls.
The absolute values of PFR were significantly higher in controls (Fig. 1), 
compared with DM2 patients (Fig. 2) (P<0.001).
Fig. 1–A) 48-year-old normoglycemic man. Left ventricular filling volume versus time 
curve and its first derivative, the peak filling rate curve. The LV volume versus time curve 
and its first derivative (LV dV/dt) are obtained after the endocardial delineation of all LV 
short-axis slices across all temporal phases. The peak filling rate is the steepest tangent 
to the first part of the filling curve and represents the most rapid ventricular filling. 
The value obtained was 394 mL/s. B) 45-year-old man with type 2 diabetes mellitus. 
Left ventricular filling volume versus time curve and the peak filling rate obtained (269 
mL/s). 
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Table 1 Characteristics of the study population
Characteristics DM2 group 
(n=41)
Controls 
(n=21)
P
Age (years), mean ± SD 58.2±7.2 54.9±6.5 0.078
Male gender, n (%) 20 (49) 12 (57) 0.533
BSA (m2), mean ± SD 1.85±0.21 1.80±0.16 0.359
BMI (kg/ m2), mean ± SD 29.3±4.6 25.0±1.7 < 0.001
Diabetes duration (y), mean ± SD 13.3±8.9 -
Hypertension n(%)a 30 (73) 6 (29) 0.001
LV EDV (mL), mean ± SD 96.3±20.8 118.7±25.1 0.001
LV EDV / BSA (mL/m2), mean ± SD 52.2±10.9 65.6±11.4 < 0.001
LV SV (mL), mean ± SD 63.7±14.5 79.9±14.4 < 0.001
LV EF (%), mean ± SD 66.7±8.0 67.9±5.3 0.485
LV mass / BSA (g/m2), mean ± SD 68.2±13.6 65.6±10.0 0.474
LV PFR (mL/s), mean ± SD 293.2±51.7 375.7±102.8 < 0.001
LV PFR/EDV (mL/s), mean ± SD 3.1±0.7 3.2±0.8 0.616
LV PFR/SV (mL/s), mean ± SD 4.7±1.1 4.7±1.0 0.979
Mitral peak E velocity (cm/s), mean ± SD 42.8±10.7 48.8±10.4 0.040
Mitral peak A velocity (cm/s), mean ± SD 49.8±11.2 45.0±8.6 0.069
Mitral E/A ratio, mean ± SD 0.88±0.3 1.1±0.3 0.002
Note—Dash (—) indicates not applicable. DM2 = type 2 diabetes mellitus, BSA = body surface area, 
BMI = body mass index, LV = left ventricular, EDV = end-diastolic volume, SV = stroke volume, LVEF = 
left ventricular ejection fraction, PFR = peak filling rate, E/A ratio = peak E velocity–to–peak A velocity 
ratio. Blood pressure > 140/90 mm Hg or treatment with antihypertensive medication.
The values of PFR indexed to end-diastolic volume (EDV) and stroke 
volume (SV) in DM2 patients and control subjects were similar (P = 0.616, 
P = 0.979, respectively).
An analysis of the transmitral parameters showed lower mitral peak 
E velocities (P = 0.040) and lower E/A ratios (P = 0.002) in DM2 patients 
compared with control subjects. Mitral peak A velocities were higher in 
the DM2 group, although not significantly so (P = 0.069).
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To further address the relationship between hypertension and diastolic 
dysfunction in the patient population, we performed a subgroup analysis 
of the parameters of diastolic dysfunction in the DM2 group according 
to the presence or absence of hypertension. The results obtained are 
presented in Table 2.
In this subgroup comparison, all parameters of LV diastolic function were 
similar in both groups.
Table 2 Left ventricular diastolic function parameters in the DM2 group according to 
the presence of systemic arterial hypertension 
Parameters DM2 only group 
(n=11), Mean±SD
DM2 and HT group 
(n=30), Mean±SD
P
LV PFR (mL/s) 293.0±52.6 292.1±52.7 0.964
LV PFR/EDV (mL/s) 3.0±0.8 3.2±0.7 0.356
LV PFR/SV (mL/s) 4.5±1.1 4.8±1.2 0.454
Mitral peak E velocity (cm/s) 43.0±9.4 42.8±11.4 0.948
Mitral peak A velocity (cm/s) 50.4±6.5 49.5±12.6 0.774
Mitral E/A ratio 0.85±0.19 0.89±0.27 0.610
Note—PFR = peak filling rate, EDV = end-diastolic volume, SV = stroke volume, E/A ratio = peak E 
velocity–to–peak A velocity ratio.
Coronary atherosclerosis
In the DM2 group, average CAC score was 344 ±754 (range 0 – 4697). CAC 
was was less than 10 in 18 (44%) DM2 patients. Nine of 42 (21%) DM2 
patients had CAC scores greater than 10.
Parameters of diastolic function and calcium score
Table 3 shows baseline and left ventricular systolic and diastolic parameters 
of DM2 subjects according to the presence or absence of coronary artery 
calcification. 
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Table 3 Characteristics of patients with DM2 according to the presence or absence of 
coronary calcification
Calcium 
score > 0 
(n=27)
Calcium 
score = 0 
(n=14)
P
Age (y), mean ± SD 60.2±6.7 54.6±6.8 0.018
Male gender, n (%) 15 (56) 5 (36) 0.228
BSA (m2), mean ± SD 1.86±0.17 1.84±0.27 0.763
BMI (kg/m2), mean ± SD 29.1±4.5 30.0±4.6 0.550
Diabetes duration (y), mean ± SD 14.9±9.0 9.4±8.4 0.060
Hypertension, n(%)a 19 (70) 11 (79) 0.574
LV EDV (mL), mean ± SD 97.5±22.7 93.9±17.1 0.567
LV EDV / BSA (mL/m2), mean ± SD 52.4±10.8 51.8±11.4 0.863
LV SV (mL), mean ± SD 65.9±15.6 59.4±11.5 0.139
LV EF (%), mean ± SD 68.3±8.9 63.7±6.6 0.065
LV mass / BSA (g/m2), mean ± SD 70.9±14.3 63.1±10.6 0.055
LV PFR (mL/s), mean ± SD 286.6±54.2 306.4±45.3 0.220
LV PFR/EDV (mL/s), mean ± SD 3.0±0.7 3.4±0.8 0.142
LV PFR/SV (mL/s), mean ± SD 4.4±1.0 5.3±1.4 0.038
Mitral peak E velocity (cm/s), mean ± SD 40.1±11.3 48.0±7.3 0.024
Mitral peak A velocity (cm/s), mean ± SD 49.8±13.2 49.8±6.2 0.997
Mitral E/A ratio, mean ± SD 0.83±0.3 0.96±0.2 0.086
BSA, body surface area; BMI, body-mass index; LV, left ventricle; EDV, end diastolic volume; SV, stroke 
volume; EF, ejection fraction; PFR, peak filling rate.
aBlood pressure > 140/90 mmHg or treatment with anti-hypertensive medication.
DM2 patients with coronary calcification were older (P=0.018) and 
had longer duration of diabetes mellitus, although not significantly so 
(P=0.060). Comparing DM2 subjects according to the presence or absence 
of coronary calcification, we found no differences in terms of gender, BSA, 
BMI or the presence of hypertension. The analysis of LV systolic function 
and LV mass showed also no statistically significant difference between 
DM2 with or without coronary calcification.
Regarding parameters of diastolic function, DM2 subjects with coronary 
calcification showed lower PFR/SV (Figs. 3A and 3B) (P=0.038) and lower 
mitral peak E velocities (P=0.024), compared to DM2 subjects without 
coronary calcification (Figs. 4A and 4B).
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Fig. 3-67-year-old man with type 2 diabetes mellitus and coronary artery calcification.
A, Left ventricular filling volume versus time curve and peak filling rate (PFR) obtained 
(357 mL/s). PFR is steepest tangent (line) to first part of filling curve and represents 
most rapid ventricular filling. PFR indexed to stroke volume (PFR/SV) was 3.72 mL/s.
B, CT image used for coronary artery calcium scoring shows coronary artery calcifications 
(arrow). Agatston calcium score calculated by CT was 410.
Fig. 4—55-year-old woman with type 2 diabetes mellitus and no coronary artery 
calcification.
A, Left ventricular filling volume versus time curve and peak filling rate (PFR) obtained 
(347 mL/s). PFR is steepest tangent (line) to first part of filling curve and represents 
most rapid ventricular filling. PFR indexed to stroke volume (PFR/SV) was 5.18 mL/s.
B, CT image used for coronary artery calcium scoring shows no coronary artery 
calcifications. Agatston calcium score calculated by CT was 0.
Univariable and Multivariable analysis
In the DM2 group, an increasing CAC score was negatively correlated with 
PFR/SV (r=-0.68, P<0.001; Fig. 5).
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Fig. 5 – Relationship of PFR / SV with CAC
By multivariable analysis, PFR/SV was independently associated with the 
presence of coronary calcification (β = –1.5, P = 0.005) after adjustment for 
age, sex, BMI, presence of hypertension, diabetes duration, LVEF, and LV 
mass index.
5. Discussion
In this study, coronary artery calcium score and parameters of diastolic 
function in patients with type 2 diabetes mellitus were investigated. The 
major observations were as follows: A) Differences in diastolic function 
were observed between DM2 patients and control subjects, in particular, 
in LV PFR values, mitral peak E velocities and E/A ratios; B) Parameters of 
diastolic function were different between DM2 patients with or without 
coronary calcification, in particular LV PFR/SV values and mitral peak E 
velocities.
Differences in left ventricular diastolic measures 
Left ventricular filling profiles have been used to assess diastolic function 
by other imaging investigations, such as radionuclide cineangiography 
and SPECT. Similar applications for CMR imaging have been impractical 
because manual planimetry of all LV images across all temporal phases 
would typically require tracing of > 200 images per patient. With the 
improvements in post-processing tools it is now possible to semi-
automatically segment all phases and quickly provide the time-varying 
course of the LV volume during the cardiac cycle. The ventricular relaxation 
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abnormalities can be diagnosed by a low peak filling rate. This evaluation 
is based on conventional short-axis sequences, without the necessity 
to perform a dedicated acquisition. The use of indexed values of PFR to 
EDV and SV minimizes the dependency of PFR from EDV and heart rate. 
We demonstrated that the left ventricular peak filling rate can be easily 
obtained as an addition to the assessment of LV systolic function with 
semi-automatic contour detection and it may become a valuable asset to 
the evaluation of LV diastolic function.
In the current study, parameters of LV diastolic function were impaired 
in DM2 patients compared with normoglycemic controls. Mitral peak 
E velocity, E/A ratio and LV peak filling rate were lower in DM2 patients, 
indicating impaired myocardial relaxation and/or increased myocardial 
stiffness, which are the hallmarks of diastolic dysfunction (18). DM2-related 
changes in LV diastolic properties are well recognized with a decrease in 
early diastolic filling, directly influenced by abnormal LV relaxation, mainly 
due to a derangement in energy supply, and an increased passive stiffness 
due to remodeling (19).
We acknowledge that coexisting arterial hypertension augments the 
impairment of LV diastolic function in diabetic patients, and may partially 
explain the changes reported.
Interestingly, Di Bonito et al observed diastolic dysfunction in 16 
normotensive patients with type 2 diabetes without microvascular 
complications and a short disease duration (even less than 1  year) 
(20). Likewise, previous studies showed that more than 40% to 75% of 
normotensive diabetic patients under excellent glycemic control had 
diastolic dysfunction (1, 2, 21). In our study parameters of diastolic function 
were not different in the patients with DM2 and HT, compared to patients 
with DM2 without HT.
Diastolic function and coronary atherosclerosis
Our study in DM2 patients shows an association between diastolic function 
assessed by CMR and coronary calcification assessed by CT.
In our cohort of DM2 patients, lower PFR/SV and mitral peak E values 
were significantly associated with coronary calcification.  Furthermore, 
the presence of coronary calcification was independently associated 
with PFR/SV, increasing the strength of this association. Our results are 
consistent with the findings of other studies. Colletti et al (13) studied 
386 subjects, including 39 patients with diabetes mellitus, and also found 
a relation of a CAC > 100 with decreased MRI-derived parameters of LV 
diastolic filling. Scholte et al (22) have reported similar conclusions. Their 
results point to an association of coronary atherosclerosis with subclinical 
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left ventricular dysfunction evaluated in type 2 diabetic patients, using 
echocardiographic derived indices of diastolic (transmitral and pulmonary 
vein flow recording) and systolic function (global longitudinal strain) (22). 
Mechanisms underlying the relationship of subclinical atherosclerosis and 
diastolic function are probably related to vascular function. 
Poulsen et al (23) suggested that abnormal LV filling in DM2 patients is 
closely associated with abnormal myocardial perfusion on myocardial 
perfusion scintigraphy. Macrovascular coronary disease could also 
contribute to this subclinical myocardial damage (22). In coronary 
macrovasculature, formation of atheroma may lead to luminal obliteration, 
recurrent thrombosis, distal embolization, and clinically silent micro-
infarctions (11).
The findings of the present study contribute to the available knowledge, 
favoring the hypothesis that there is a link between subclinical LV diastolic 
dysfunction and asymptomatic atherosclerosis.
Our DM2 patients with coronary artery calcification had greater LV mass 
than the DM2 patients without coronary calcification, but the difference 
did not quite achieve acceptable levels of statistical significance (P=0.055). 
LV mass represents an end point of cumulative LV insult and although 
not a diagnostic criteria for LV diastolic dysfunction, increased LV mass 
is associated with diastolic dysfunction, from abnormal relaxation to 
coexistent restrictive physiology due to increased myocardial stiffness 
(24). Systemic arterial hypertension and diabetes mellitus are known 
causes LV hypertrophy. Notwithstanding the high prevalence of arterial 
hypertension in our population, none of our subjects had an LV mass 
above the normal range (LV mass indexed to BSA > 86g/m2 for males and 
>72g/m2 for females) (25, 26).
The originality of our study is the use of CMR-derived parameters of 
diastolic function and the relatively high number of DM2 patients with 
low CAC. We had a relatively large percentage of DM2 patients with CAC 
equal to zero, something that we were not expecting in a population of 
DM2 patients between 45 and 72 years of age.
A basic limitation of this study must be acknowledged. This was a cross-
sectional study with a relatively small number of subjects; therefore, 
studies using larger patient cohorts are needed to clarify the association 
between LV diastolic function and coronary atherosclerosis.
Our findings are limited by an inability to eliminate causal relationships 
with important clinical factors, as medication used, serum concentrations 
of glucose, and HbA1c, dyslipidemia, retinopathy, microabuminuria and 
smoking status. Also, the high prevalence of hypertension in our population 
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makes it difficult to interpret the findings and clarify the responsibility of 
diabetes in the results obtained. 
The possibility of influence of myocardial ischemia on LV diastolic function 
cannot be completely excluded. The evaluation of coronary stenosis 
and plaque characterization was not performed in our study, since CT 
angiography is not recommended in asymptomatic type 2 diabetic 
patients. Since myocardial perfusion, endothelial function, coronary flow 
reserve and arterial stiffness were not evaluated in the present study, a 
more comprehensive understanding of the pathophysiological process 
should be the focus of future research.
We considered that the analysis of cine and transmitral flow images 
was sufficient to exclude left-sided valvular disease as a potential pitfall 
of abnormal transmitral flow. Regarding the exclusion of infiltrative 
myocardial disease, we did not study myocardial delayed enhancement 
nor did we performed endomyocardial biopsy. Nevertheless, none of our 
subjects had increased LV myocardial end-diastolic thickness, pericardial 
thickening, pericardial effusion or pleural effusion.
Recent findings (27) shows improvement in transmitral flow assessment 
by applying three-dimensional three- directional velocity-encoding, over 
the conventional approach of two-dimensional one- directional through-
plane velocity-encoded MRI with a fixed acquisition plane used in our 
study. 
Normalizing early mitral velocity (E) for the influence of myocardial 
relaxation by combining E with early diastolic mitral septal tissue velocity 
(Ea) may be performed by MR tissue phase contrast imaging, and this is an 
important parameter of diastolic function that has been established (28). 
On the other hand there are still conflicting data regarding the relation of 
E/Ea ratio and LV filling pressure (29, 30).
This study highlights certain key points for the routine use of CMR to study 
diastolic function in diabetic patients and the relation of diastolic function 
with coronary atherosclerosis. Firstly, CMR shows a decrease in diastolic 
function in DM2 and may allow the diagnosis of subclinical diastolic 
dysfunction in this high-risk population. Secondly, diastolic function is 
possibly related to the presence of coronary atherosclerosis. 
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1. Abstract
Background
Coronary artery calcium (CAC) measurement reflects coronary 
atherosclerosis and predicts coronary events beyond conventional 
risk factors. We sought to evaluate the prevalence and severity of CAC 
scores in asymptomatic diabetes, and explore its association with other 
conventional risk factors of atherosclerosis.
Methods
We prospectively studied 66 asymptomatic subjects with type 2 diabetes 
mellitus aged 40-75 years (mean age 60,2 years) who underwent coronary 
calcium CT scanning to assess CAC score. Clinical, demographic and 
laboratorial data were collected. Carotid atherosclerosis was studied by 
carotid ultrasonography. Statistical analysis was performed.
Results
In our population of asymptomatic subjects with type 2 diabetes mellitus, 
coronary calcified plaque was found in 70% of subjects. In 41% of subjects, 
the CAC score was <10; in 27% of subjects, the CAC score was > 400. 
There was a statistically positive correlation of CAC score with age (rho = 
0.257; P = 0.037), duration of diabetes (rho = 0.327; P = 0.008) and carotid 
atherosclerosis (rho = 0.420; P < 0.001). In the multivariate analysis, male 
gender (P < 0.001) and diabetes duration (P = 0.002) demonstrated to be 
independent predictors of the CAC score.
Conclusion
In asymptomatic patients with type 2 diabetes mellitus, disease duration 
is an independent determinant of CAC score and could explain the 
heterogeneity of CAC scores observed in this population. These findings 
emphasize the critical importance of aggressive cardiovascular disease 
risk reduction in patients with type 2 diabetes mellitus early in the course 
of the disease.
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2. Introduction
Coronary artery disease (CAD) is a major cause of death and impairment 
of quality of life (1) in patients with type 2 diabetes mellitus. However, 
type 2 diabetic patients may have long-standing subclinical coronary 
artery disease (2). Thus, early detection of CAD may improve prognosis (3). 
Cardiovascular risk assessment based on conventional risk factors proved 
to be consistently unreliable in this high risk population, since they not 
directly reflect structural and functional changes in arteries associated 
with CAD (4, 5). 
In asymptomatic type 2 diabetic patients, few studies have investigated 
the association of coronary calcium with other traditional risk factors 
of CAD or with other markers of peripheral atherosclerosis, such as 
ultrasonographically assessed carotid atherosclerosis (6).
Previously published reports have demonstrated, in diabetes mellitus, 
greater coronary artery calcium (CAC) score (7-10). The present study 
supplements the existing reports of the association between CAC score 
on CT and asymptomatic diabetes, and explores its association with other 
risk factors of CAD and with carotid atherosclerosis. 
Our hypothesis was that asymptomatic subjects with type 2 diabetes 
mellitus would show a wide range of CAC scores, and we sought to 
investigate what factors could influence the CAC score in this population. 
3. Materials and methods
3.1. Study population
Sixty-six patients (31 women and 35 men) with type 2 diabetes mellitus 
were prospectively recruited based on referral to the outpatient clinical 
department of diabetology of our institution. Detailed information 
regarding symptoms, physical examination, medical history and risk 
factors were collected prospectively at the time of presentation. Patients 
were included if they met the following inclusion criteria: age between 40-
75 years, no symptoms or history of overt heart disease (cardiomyopathy, 
coronary artery disease or valvular heart disease) and therapy for DM2 
including oral hypoglycaemic agent or insulin.
Hypertension was defined as a blood pressure >140/90 mm Hg or 
treatment with antihypertensive medication. Hypercholesterolemia was 
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defined as a total cholesterol level > 190 mg/dL or use of lipid-lowering 
medication. There was no history of smoking habits in our population.
Exclusion criteria were: severely uncontrolled diabetes mellitus (glycated 
hemoglobin > 12%), uncontrolled blood pressure at rest (defined as 
systolic blood pressure > 180 mm Hg and/or diastolic blood pressure > 100 
mm Hg) and the presence of ventricular and supraventricular arrhythmias.
The study was approved by our institutional ethics committee. Each 
subject gave written informed consent.
3.2. Coronary artery calcium score, data acquisition 
and analysis 
Agatston score was performed using a 64-slice CT scanner (LightSpeed 
VCT XT, GE Healthcare, Milwaukee, USA). For this purpose, a non-enhanced 
low-dose ECG-gated scan was performed with prospective triggering 
at 75% of the R–R interval. All scans included the entire coronary tree 
and were done with breath held in inspiration. Scan parameters were as 
follows: field of view of 25 cm, slice thickness and increment of 2.5 mm, 
gantry rotation time 0.35 s, tube current 100–400 mA, and tube voltage 
120 kV. 
CAC score was determined by an experienced observer using dedicated 
software (‘SmartScore’, GE Healthcare, Milwaukee, USA). Total CAC score 
was calculated for each patient using the Agatston method (11). 
3.3. Carotid Ultrasound study
Scanning of the extra-cranial common carotid artery, the carotid bulb, and 
the internal carotid artery in the neck was performed by an experienced 
observer bilaterally in the longitudinal and transversal planes, using a GE 
Healthcare logic 9 with a 9 linear (8 MHz) probe. Carotid intima-media 
thickness (CIMT) was measured in the common carotid artery as the 
distance between 2 parallel echogenic lines corresponding to the blood-
intima and media-adventitia interface on the posterior wall of the artery. 
Determinations of carotid intima-media thickness were performed at 
the site of the thickest point and values below 0.8 mm were considered 
as normal. Localized elevated lesions with maximum thickness of more 
than 1 mm, having a point of inflection on the surface of the intima-
media complex, were defined as “plaques”. Stenosis was defined as > 
50% occlusion, according to established consensus (12). Patients were 
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categorized in three groups: Group 1, no atherosclerosis (normal carotid 
ultrasound study); Group 2, mild atherosclerosis (presence of increased 
CIMT); Group 3, moderate to severe atherosclerosis (presence of carotid 
plaque or stenosis).
3.4. Statistical analysis
All continuous variables were tested for normal distribution. All normally 
distributed data are expressed as means ± standard deviations. Categorical 
variables are expressed as counts and percentages. The distribution of 
Agatston scores was skewed, and therefore, medians and ranges were 
reported. 
Logarithmic transformation of Agatston scores, log (total calcium score 
+1), was used for parametric evaluation.
Bivariable correlations of CAC scores were performed using the Pearson or 
Spearman method as appropriate. 
Cross-tabulated statistics were provided in the categorical comparison 
between the Agatston groups, and the level of significance was determined 
using the Chi-Square test. Multiple linear regression analysis was used for 
prediction of LnAgatston score. P-values of less than 0.05 were considered 
statistically significant. All computations were performed using software 
(SPSS, version 20.0; SPSS, Chicago, IL, USA).
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4. Results
Baseline characteristics of the study population are presented in Table 1.
Table 1 Baseline characteristics of the study population 
DM2 subjects 
(n=66)
Age (years) 60.2±7.4
Male gender, n (%) 35 (53)
Height (cm) 162.3±9.9
Weight (kg) 78.7±12
Body-mass index (kg/m2) 30.1±5.3
Diabetes duration, years 13.6±8.9
Hypertension*, n (%) 46 (70)
Hypercholesterolemia†, n (%) 30 (46)
Glycosylated hemoglobin (%) 9.2±2.2
Agatston score 534.6±1021.5
LnAgatston 3.65±2.98
LnCAC, logarithmically transformed CAC score; BMI, body mass index 
Data are averages ± SDs or numbers of patients (percentages). 
* Blood pressure > 140/90 mm Hg or treatment with antihypertensive medication. 
† Total cholesterol level > 190 mg/dL or use of cholesterol-lowering medication.
Mean CAC score was 535 ±1021 (range 0 – 4697) in the total population. 
In 20 patients (30%) CAC score was absent; in 27 patients (41%) CAC score 
was <10; in 36 patients (55%) CAC score was < 100; in 18 patients (27%) 
CAC score was > 400.
Regarding extra-cranial carotid atherosclerosis, 14% of the subjects 
(n=9) had a normal carotid ultrasound study. In 22 patients (33%) carotid 
ultrasound found increased CIMT; in 33 patients (50%) were reported non 
significative plaques and in 2 patients (3%) were diagnosed with carotid 
stenosis.
3.1. Determinants of coronary calcium score
Logarithmic transformed CAC score showed a statistically positive 
correlation with age, duration of diabetes (Fig. 1) and carotid atherosclerosis. 
The results are presented in Table 2.
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Fig. 1 – Relationship of Agatston score with duration of diabetes
Table 2  Correlation between LnAgatston scores and other parameters.
rho P value
Age (years) 0.257 0.037
Height (cm) 0.203 0.201
Weight (kg) 0.133 0.288
BMI (kg/m2) -0.147 0.240
Diabetes duration, years 0.327 0.008
Glycosylated hemoglobin (%) -0.211 0.091
Carotid atherosclerosis 0.420 <0.001
LnCAC, logarithmically transformed CAC score; BMI, body mass index
To evaluate the relation of gender, hypertension and hypercholesterolemia 
with CAC scores we performed a Chi-squared analysis. The results are 
presented in table 3. Male gender was significantly associated with an 
Agatston score > 10.
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Table 3 Relation of Agatston scores with gender, hypertension and hypercholesterolemia
CAC score 
< 10
(n=27)
CAC score 
>=10
(n=39)
P 
Value
Male gender, n (%) 9 (33) 26 (67) 0.008
Hypertension*, n (%) 20 (74) 26 (67) 0.520
Hypercholesterolemia†, n (%) 13 (48) 17 (44) 0.715
Data are numbers of patients (percentages). 
* Blood pressure > 140/90 mm Hg or treatment with antihypertensive medication. 
† Total cholesterol level > 190 mg/dL or use of cholesterol-lowering medication.
In order to determine the factors affecting the LnCAC score, a model 
was created with age, male gender, duration of diabetes and carotid 
atherosclerosis (Table 4). Regression analysis predicted male gender and 
diabetes duration as statistically significant factors affecting the LnCAC 
score (Table 4).
Table 4  Predictors of CAC score identified by multiple linear regression analysis
β P value 95% confidence 
interval
Age, years -0.003 0.948 -0.097 -0 .090
Male gender 2.706 <0.001 1.466 - 3.946
Diabetes duration, years 0.117 0.002 0.046 - .189
Carotid atherosclerosis 0.755 0.109 -0.173 - 1.683
5. Discussion
IIn this study, coronary artery calcium score and carotid atherosclerosis in 
asymptomatic patients with type 2 diabetes mellitus were investigated. 
The major observations were as follows: 
First, CT could detect coronary calcified plaques in 70% of asymptomatic 
patients with type 2 diabetes. In addition, in 27% of patients a markedly 
elevated CAC score (>400) was observed. Furthermore, we had a relatively 
large percentage (41%) of type 2 diabetes mellitus patients with CAC 
score < 10, something that we were not expecting in a population of type 
2 diabetes mellitus patients between 45 and 72 years of age.
After correction for traditional risk factors, male gender and diabetes 
duration were found to be independent predictors of increasing coronary 
calcium scores.
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In our population, carotid atherosclerosis was not an independent 
predictor of coronary calcium scores.
When compared to other traditional risk scoring systems, calcium 
scores have been shown to be significantly superior in predicting silent 
myocardial ischemia and short-term outcomes, compared to United 
Kingdom Prospective Diabetes Study Risk Score, UKPDS and Framingham 
risk score (13). In an 8-year follow up study it was shown that those who 
had higher CAC score (>400) had significantly higher prevalence of cardiac 
events compared to those with lower scores (14).
However, on the other side, knowing that diabetics constitute a higher risk 
group, studies showed that having a low calcium score could be helpful 
to re-stratify them into a lower risk category with low cardiac events and 
excellent survival rates (15). This was also demonstrated by Anand et al 
that prospectively measured CAC score in asymptomatic type 2 diabetic 
subjects without prior cardiovascular disease. No cardiac events or 
perfusion abnormalities occurred in subjects with CAC score ≤10 up until 
2 years of follow-up (13). In a 5-year follow up study for 903 asymptomatic 
diabetics, patients suffering from diabetes with no coronary artery calcium 
demonstrated a survival similar to that of individuals without diabetes and 
no detectable calcium (3). 
Using coronary CT angiography in asymptomatic patients remains 
controversial, primarily because of the higher radiation dose, added cost, 
and use of nephrotoxic contrast, but it has the potential to identify useful 
data beyond what is derived from CAC score.
As detailed in the 2010 Guideline for Appropriate Use Criteria for Cardiac 
Computed Tomography, coronary CT angiography is not recommended 
for cardiovascular risk assessment in asymptomatic adults (16).
The relation of male gender with coronary atherosclerosis demonstrated 
in our study is in line with previous publications. In the general population, 
as with the prevalence of clinical coronary disease, CAC scores are higher 
in men compared to women (17). One of the largest studies that examined 
the age and gender distribution of CAC score in asymptomatic diabetic 
subjects found that at any given age, men exhibited significantly greater 
calcified plaque burden, as compared with women (10).
Moreover, the influence of age at onset and duration on the impact of 
diabetes on cardiovascular disease risk is not fully established.
Previous studies (18-20) suggested that cardiovascular disease risk in 
patients with diabetes escalates significantly with disease duration. A 
recent study evaluating the prevalence and severity of calcified plaque in 
coronary arteries in patients aged <40 years included 142 diabetics and 
Graça B, Ferreira MJ, Donato P, Gomes L, Castelo-Branco M, and Caseiro-Alves F. 
Submited
Disease duration as a major determinant of increased coronary artery calcium score in asymptomatic DM2     |     145
demonstrated that a high percentage of young patients with diabetes 
have detectable coronary atherosclerosis (21).
Nevertheless, the impact of diabetes duration on coronary artery 
calcification is not yet established.
In this asymptomatic population of type 2 diabetes mellitus subjects, 
a significant relation was observed between disease duration and the 
presence of atherosclerosis determined by the CAC score. Furthermore, 
after correction for traditional risk factors, diabetes duration was found to 
be an independent predictor of the CAC score.
A longer exposure to chronic hyperglycemia may be the explanation. Other 
factors, such as worsening beta-cell function and thus insulin insufficiency, 
could also play a role (22). Beta-cell function is not easy to measure in the 
clinical practice. Because chronic hyperglycemia and insulin insufficiency 
generally coexist in persons with longer diabetes duration, it is difficult 
to determine their independent roles. Irrespective of mechanisms, the 
clinical implication is that this emphasizes the need to be aggressive with 
cardiovascular disease risk reduction in patients with type 2 diabetes early 
in the course of the disease.
The relationship between carotid CIMT and coronary artery disease on 
CT has been previously studied in different populations. A recent study 
demonstrated that carotid plaque and increased CIMT are associated 
with coronary artery disease on coronary CT angiography in a mostly 
nondiabetic white cohort (3). Previous studies in the general population 
using electron beam CT also found an association between carotid artery 
disease and CAC score (24, 25). 
Fewer data are available concerning the relation of carotid atherosclerosis 
to coronary artery disease in asymptomatic patients with diabetes. 
Djaberi et al (6) studied 150 asymptomatic diabetic patients and found 
a significant relation between CIMT and the presence of atherosclerosis 
determined by CAC score and coronary CT angiography. A recent study 
evaluated 241 asymptomatic type 2 diabetic patients and concluded that 
there is an association of CIMT with coronary artery stenosis assessed by 
coronary CT angiography (26).
No study assessing the relation between carotid and coronary 
atherosclerosis incorporated other features of carotid atherosclerosis, as 
carotid plaques or stenosis.
Although we found a significant positive correlation between the severity 
of carotid atherosclerosis and CAC scores, this relation is not independent 
of gender or duration of diabetes. 
Several limitations must be acknowledged. The present analysis was 
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restricted to an evaluation of the relation between carotid atherosclerosis 
and Agatston score in diabetic patients, and assessment did not include a 
nondiabetic control group. As coronary CT angiography is accompanied 
by radiation exposure, it is not feasible to perform a similar assessment in 
asymptomatic subjects.
6. Conclusions
In conclusion, we have demonstrated that, among asymptomatic patients 
with type 2 diabetes mellitus, disease duration is an independent 
determinant of CAC score and could explain the heterogeneity of CAC 
scores observed in this population. In the light of current trends of rising 
prevalence of type 2 diabetes combined with a decrease in the age at 
onset (27), these findings emphasize the critical importance of aggressive 
cardiovascular disease risk reduction in patients with type 2 diabetes 
mellitus early in the course of the disease.
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Summary and conclusions
Diabetes mellitus is responsible for diverse cardiovascular complications 
such as increased atherosclerosis in large arteries (carotids, aorta, and 
femoral arteries) and increased coronary atherosclerosis. Coronary 
microvascular disease may contribute to cardiac pathology as well. 
Diabetes mellitus also can affect cardiac structure and function in the 
absence of changes in blood pressure and coronary artery disease, a 
condition called diabetic cardiomyopathy.
Due to the often masked symptoms of type 2 diabetes mellitus, the disease 
may only be diagnosed several years after onset when complications have 
already occurred. Often, the prognosis of patients with type 2 diabetes 
mellitus depends on the presence of cardiovascular disease.
Research on cardiovascular complications of diabetes mellitus will allow 
the development of appropriate markers and diagnostic techniques to 
identify individuals at risk, stage the disease, prognosticate, and evaluate 
therapy relevant to the cardiovascular complications of diabetes mellitus. 
The criteria for the selection of those asymptomatic patients with type 
2 diabetes that should undergo cardiac screening and the therapeutic 
consequences of screening remain controversial. Non-invasive techniques 
as markers of atherosclerosis and myocardial ischemia may aid risk 
stratification and the implementation of tailored therapy for the patient 
with type 2 diabetes mellitus.
A number of noninvasive tests are now available to detect coronary 
atherosclerotic disease, myocardial dysfunction and myocardial ischemia.
The potential of cardiovascular imaging for the assessment of cardiovascular 
complications of type 2 diabetic patients is an active field of research.
The purpose of the present research is to study the role of novel cardiac 
imaging techniques in assessing cardiovascular disease in patients with 
type 2 diabetes mellitus.
Chapter 1 provides an overview of the definition, classification, diagnosis 
and prevalence of diabetes mellitus. Moreover, are described the 
cardiovascular manifestations of diabetes mellitus and discussed the 
pathophysiological mechanisms responsible for diabetic cardiovascular 
disease.
Chapter 2 provides an overview of the background of different noninvasive 
imaging modalities that are used for the evaluation of cardiovascular 
disease in diabetes mellitus. 
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In Chapter 3 we discussed the issue of screening cardiovascular disease in 
asymptomatic diabetic patients.
In Chapter 4, we studied the prevalence and gender differences in 
subclinical LV diastolic dysfunction, using MR imaging. We concluded 
that the prevalence of some diastolic dysfunction in apparently normal 
subjects is up to 25%, and this diastolic dysfunction is higher in men than 
in women.
In Chapter 5, we prospectively assessed for the presence of left atrial 
function in asymptomatic patients with type 2 diabetes mellitus, using MR 
imaging. We concluded that left atrial function is altered in patients with 
type 2 diabetes mellitus, characterized by a reduction in reservoir and 
conduit functions, without a compromise of booster pump function. We 
have also demonstrated that type 2 diabetes mellitus was an independent 
determinant of left atrial reservoir function. These findings point out that 
left atrial dysfunction might be a component of the heart phenotype in 
type 2 diabetes mellitus.
In Chapter 6, we compared MR-derived parameters of left ventricular 
diastolic function between asymptomatic diabetic subjects and 
normoglycemic controls. We also evaluated whether these parameters 
of LV diastolic function were related to coronary atherosclerosis. We 
concluded that type 2 diabetes mellitus decreases MR-derived parameters 
of left ventricular diastolic function, and this effect is related to coronary 
atherosclerosis. 
The purpose of the study in Chapter 7 was to evaluate the prevalence 
of coronary and carotid atherosclerosis in asymptomatic patients with 
type 2 diabetes mellitus. The major observations were as follows: First, CT 
could detect coronary calcified plaques in 70% of asymptomatic patients 
with type 2 diabetes. In addition, in 27% of patients a markedly elevated 
Agatston score (>400) was observed. Furthermore, we had a relatively 
large percentage (41%) of type 2 diabetes mellitus patients with Agatston 
score < 10. After correction for traditional risk factors, male gender and 
diabetes duration were found to be independent predictors of increasing 
coronary calcium score. Carotid atherosclerosis was not an independent 
predictor of coronary calcium scores.
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Conclusions and future perspectives
In this thesis, we evaluated several different cardiac imaging techniques 
for the assessment of complications in asymptomatic patients with type 2 
diabetes mellitus. 
Left ventricular diastolic dysfunction seems to be a biomarker of 
asymptomatic type 2 diabetes mellitus, but may be present in a significative 
percentage of apparently normal subjects.
Our study was one of the pioneers in using novel MRI imaging parameters 
to identify left atrial dysfunction in type 2 diabetes mellitus.
We demonstrated that asymptomatic subjects with type 2 diabetes 
mellitus show a wide range of coronary calcium scores, and that disease 
duration is an independent predictor of increasing coronary calcifications. 
We also demonstrated that the presence of coronary calcification is related 
to left ventricular diastolic dysfunction.
The relationship of these cardiac imaging biomarkers with other biological 
and genetical markers of target-organ damage will be addressed in future 
studies.
The prognostic value of all these cardiac imaging biomarkers for risk 
stratification of asymptomatic patients with type 2 diabetes mellitus will 
be determined in future follow-up studies. 
The challenge is to identify those subjects at increased risk for cardiovascular 
morbidity and mortality, adequate treatment and improve the outcome 
of these patients. 
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Resumo e conclusões
A diabetes mellitus é responsável por diversas complicações 
cardiovasculares, incluindo aterosclerose em artérias de grande calibre 
(carótidas, aorta e artérias femorais) e nas artérias coronárias. A doença 
microvascular coronária é um dos outros mecanismos de doença coronária 
na diabetes mellitus. Por fim, a diabetes mellitus pode também afectar 
a estrutura e a função cardíaca na ausência de alterações na pressão 
arterial e de doença arterial coronária, uma condição denominada 
miocardiomiopatia diabética .
Pela natureza tipicamente assintomática da diabetes mellitus tipo 2, o 
diagnóstico pode ser efectuado muito tardiamente, quando já ocorreram 
complicações graves. Frequentemente, o prognóstico dos pacientes 
com diabetes mellitus tipo 2 depende da presença e do grau de doença 
cardiovascular.
A investigação no campo das complicações cardiovasculares de diabetes 
mellitus poderá permitir o desenvolvimento de marcadores e técnicas de 
diagnóstico, no sentido de melhor identificar os pacientes de risco, estadiar 
a doença, estabelecer o prognóstico e avaliar a terapêutica instituída. 
Não estão estabelecido os critérios de selecção de pacientes assintomáticos 
com diabetes mellitus tipo 2 que devem efectuar rastreio de doença 
cardiovascular, bem como as potenciais consequências terapêuticas 
desse rastreio.
Uma série de técnicas não-invasivas estão agora disponíveis para detectar 
doença coronária aterosclerótica, disfunção e isquémia miocárdica.
O potencial da imagiologia cardíaca na avaliação das complicações 
cardiovasculares em pacientes com diabetes tipo 2 é um campo activo de 
pesquisa.
O objectivo da presente investigação é estudar o papel de novos métodos 
de imagiologia cardíaca na avaliação de doença cardiovascular em 
pacientes com diabetes tipo 2.
No capítulo 1, foi efectuada uma revisão da definição, classificação, 
diagnóstico e epidemiologia da diabetes mellitus. Além disso, são descritas 
as manifestações cardiovasculares da diabetes mellitus e discutidos os 
mecanismos fisiopatológicos responsáveis  pela doença cardiovascular na 
diabetes.
O capítulo 2 fornece uma visão geral das diferentes modalidades não-
invasivas de imagem que são utilizadas para a avaliação da doença 
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cardiovascular em pacientes com diabetes mellitus.
O capítulo 3 discute a temática do rastreio da doença cardiovascular em 
diabéticos assintomáticos.
O objectivo do trabalho apresentado no capítulo 4 foi avaliar a prevalência 
e diferenças de género na disfunção diastólica do ventrículo esquerdo em 
controlos assintomáticos, através de estudo de RM cardíaca. Concluiu-se 
que a prevalência de disfunção diastólica em indivíduos aparentemente 
normais é de até 25%, e esta disfunção diastólica é maior em homens do 
que em mulheres.
No capítulo 5, estudámos a função da aurícula esquerda em diabéticos 
assintomáticos, através de RM. Concluiu-se que a função da aurícula 
esquerda está alterada em pacientes com diabetes mellitus tipo 2, 
caracterizado por uma redução nas funções de reservatório e conduto, 
sem um compromisso da contracção activa. Também demonstramos que 
a diabetes mellitus tipo 2 é um determinante independente da função 
de reservatório da aurícula esquerda. Estes resultados indicam que a 
disfunção da aurícula esquerda pode ser um componente do fenótipo 
cardíaco em pacientes com diabetes mellitus tipo 2 .
No capítulo 6 comparámos parâmetros de disfunção diastólica entre 
diabéticos assintomáticos e controlos, utilizando a RM cardíaca. Além 
disso, avaliámos a relação entre marcadores de disfunção diastólica 
do ventrículo esquerdo e a arteriosclerose coronária. Concluiu-se que 
a diabetes mellitus tipo 2 associa-se a redução da função diastólica do 
ventrículo esquerdo, e que este efeito está relacionado com a aterosclerose 
coronária.
O objectivo do estudo descrito no capítulo 7 foi avaliar a prevalência de 
aterosclerose coronária e carotídea em pacientes assintomáticos com 
diabetes mellitus tipo 2. As principais observações foram as seguintes: 
a TC detectou placas calcificadas coronárias em 70% dos pacientes 
assintomáticos com diabetes tipo 2. Além disso, em 27 % dos pacientes 
foi observada um score de cálcio marcadamente elevado ( > 400 ). Por 
fim, uma percentagem relativamente grande (41%) dos pacientes com 
diabetes mellitus tipo 2 tinha um score de cálcio <10. Após a correcção dos 
fatores de risco tradicionais, o género masculino e duração da diabetes 
demonstraram ser predictores independentes do aumento do score de 
cálcio. Não se verificou relação entre a arteriosclerose coronária e o score 
de cálcio nas artérias coronárias. 
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Conclusões e perspectivas futuras
Na presente tese, foram avaliadas diferentes técnicas de imagem para o 
estudo de complicações cardiovasculares em pacientes assintomáticos 
com diabetes mellitus tipo 2.
A disfunção diastólica do ventrículo esquerdo parece ser um biomarcador 
de diabetes mellitus tipo 2 assintomática, mas pode também estar presente 
num número significativo de indivíduos aparentemente normais.
O nosso estudo foi um dos pioneiros no uso de novos parâmetros de 
imagem de ressonância magnética para identificar disfunção da aurícula 
esquerda na diabetes mellitus tipo 2.
Demonstramos que indivíduos assintomáticos com diabetes mellitus tipo 
2 apresentam uma grande variabilidade de scores de cálcio coronário, e 
que a duração da doença é um predictor independente do aumento do 
grau de calcificação coronária.
Demonstramos ainda que a presença de aterosclerose coronária está 
relacionada com a disfunção diastólica do ventrículo esquerdo.
A relação desses biomarcadores de imagem cardíaca com outros 
marcadores biológicos e genéticos de lesão de órgão-alvo será abordada 
em estudos futuros.
O valor prognóstico de todos esses biomarcadores de imagem cardíaca 
para estratificação do risco em pacientes assintomáticos com diabetes 
mellitus tipo 2 será determinada em estudos futuros.
O desafio será identificar os indivíduos com maior risco de morbilidade 
e mortalidade cardiovascular, adequar o tratamento e melhorar o 
prognóstico destes pacientes .
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